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INTRODUCTION
1 
INTRODUCTION 
Ovarian tumors are the most common neoplasms in women. Among the 
various gynecological tumors, the pathology of ovarian neoplasms is more 
complex, because the ovary gives rise to various types of tumors than any other 
organ. The origin of ovarian tumour is often in disparity
1
. Ovarian tumours  
accounts  for larger proportion of clinically important problems and they are 
usually dangerous because of  their silent growth.  
         Worldwide, Ovarian tumor constitutes sixth most common tumor in women. 
Ovarian carcinoma is the fifth most common malignancy in the western countries 
and ranks fourth in cancer mortality
2
. In India, Ovarian cancer is the most lethal 
gynecologic malignancy which ranks 2
nd
 after cervical cancer.  In Chennai, ovarian 
cancer stands in the third position
3
.  
       This high mortality is because of difficulty in diagnosing ovarian cancer at 
an early stage and absence of effective therapies for advanced stage disease 
4
. 
PLCO screening programme is the ongoing trail designed for effective screening of 
ovarian cancer which includes Transvaginal USG and CA 125 level. The aim of 
this programme is to diagnose ovarian tumors when they are still confined to the 
ovaries. By this the mortality of the disease is reduced and effective cure can be 
obtained
5
.  
 
2 
Ovarian carcinoma exhibits a wide range of morphological phenotypes.  
Since more than 90% of ovarian cancers are of epithelial cell origin, various 
genetic alterations occur during malignant transformation of ovarian epithelial 
cells. Several studies on the molecular pathways of carcinogenesis provides 
explanation for the different morphologic phenotypes and the prognostic behavior 
of ovarian carcinoma.  
Genomic studies on surface epithelial ovarian tumors have proposed a new 
method of classification based on their gene expression patterns. Type I tumors are 
genetically stable and are characterized by mutations in a number of different 
genes including KRAS, BRAF, PTEN, and beta-catenin. Type II tumors show high 
level of genetic instability and is characterized by mutation of TP537 
Women with a family history of ovarian carcinoma or who have BRCA 1/2 
mutations shows reduced risk for tumor development following prophylactic 
hysterectomy and bilateral salpingo-oophorectomy. Immunohistochemical markers 
like cytokeratin have been used in the diagnosis of ovarian tumors. Recently 
various studies on prognostic significance of p53, Her-2neu, overexpression in 
epithelial ovarian cancer suggests poor prognosis and decreased survival benefit. 
 
More than 30% epithelial ovarian cancer shows amplification and over- 
expression of ERBB2 gene and they are associated with worse prognosis
8
.  p53 
overexpression shows an aggressive behavior and is associated with more rapid 
3 
spread of disease. Hence IHC is used to measure the Her 2 neu and p53 protein 
overexpression present in the epithelial tumors. 
                 This study is undertaken in view of evaluating the incidence, age, 
clinical features, histopathological and immunohistochemical features of epithelial 
ovarian tumors and its prognostic significance. In addition, the recent literatures, 
journals and research publications on ovarian tumors are also reviewed. 
                             
  
 
 
 
AIMS AND OBJECTIVES 
4 
AIMS AND OBJECTIVES 
1. To evaluate the incidence and distribution of  surface epithelial ovarian 
carcinoma in patients admitted in  Institute of Obstetrics & Gynaecology, 
Egmore &  Institute of Social Obstetrics  and Kasthurbai Gandhi Hospital, 
Triplicane ,Madras Medical College, Chennai during the year 2008-2012. 
2. To study the histopathological features of epithelial ovarian carcinoma 
which includes site of involvement, tumour size, macroscopic feature, 
histological subtype, grade, stage, presence of ascites. 
3. To study the immunohistochemical expression of P53 in epithelial ovarian 
carcinoma. 
4. To study the immunohistochemical expression of Her2neu in epithelial 
ovarian carcinoma. 
5. To determine the association  of P53 and  Her2neu expression with known 
          clinicopathological factors such as age, stage, histological subtypes, grade        
          and presence of ascites, 
  
 
 
 
REVIEW OF LITERATURE 
 
5 
REVIEW OF LITERATURE    
  Surface epithelial ovarian tumors is considered as a leading cause of death 
among all gynaecological cancers. It constitutes about two-thirds of all ovarian 
cancers and 90% of ovarian cancers are malignant
47
. It usually arises sporadically 
in 90-95% of the patients. The incidence of ovarian cancer is gradually increasing 
in India with crude incidence rate of 5.2. 
Surface epithelial ovarian tumors are classified according to cell type as 
serous, mucinous, endometrioid , based on pattern of growth into cystic and solid 
based on amount of fibrous tissue, cellular atypia and invasiveness. 
Various grading system such as FIGO, WHO, Gynecologic Oncology 
Group, were in use in the past, but they are not currently in place. Silverberg and 
colleagues
9
 proposed universal grading system which includes degree of nuclear 
atypia, number of mitotic figures, formation of papillae and glands. 
In the year 2004, Malpica Anais MD et al 
10 
proposed two-tier grading 
system for serous carcinomas which depends on the degree of nuclear atypia and 
number of mitotic figures. This system later compared the results with other 
systems of grading by Shimizu/Silverberg and the FIGO. 
  
6 
EPIDEMIOLOGY  
A study conducted by I.Dos Santos Silva  and A. J. Swerdlow 
11
 
 
showed 
that there were increase in  the incidence of ovarian tumors with significant 
increase in elderly age than young. It constitutes about 0.76% per year. Highest 
rate of incidence is seen in developed countries like Scandinavia, Israel, and North 
America, whereas in developing countries and in Japan incidence rate is low
12
.  
Bouly P et al
13 
showed that incidence rate of ovarian tumors in developing 
countries less than 5 per lakh, but in developed countries it is less than 13 per lakh 
population. Risk of ovarian epithelial tumors in black women is lower than whites. 
Epithelial ovarian tumors are more common in developed countries because of  
low parity
23
 
   In a study conducted on the age-standardized incidence rates on ovarian 
cancer for the period 2001-06, highest rate of incidence were seen in Pune and 
Delhi. It ranges from 0.9 to 8.4 per 100,000 person years. This study also showed 
that the disease usually increases at the age of 35 and peaks during the age of     
55-64 yrs
14
. Surface epithelial ovarian cancer is seen commonly in postmenopausal 
women and only 20% of the cases occur in reproductive-age  group.
15
 
 
 
 
7 
RISK FACTORS 
Villard – Mackintosh L et al 16 have suggested that women on oral 
contraceptives and those who show increased parity are protected from ovarian 
carcinoma. Early menarche and late menopause are also considered to be 
significant risk factors for ovarian tumors 
13
. Another study suggests that ovarian 
cancer is more common in high socio economic group because of low fertility rates 
in these women. 
La Vecchia C. et al
17
 proved that incidence rate and mortality of ovarian 
tumors is less in younger individuals than the elderly. As the age increases the 
incidence rate also increases. 
 Fathalla MF et al 
18
hypothesis shows that during incessant ovulation the 
surface epithelium of the ovary undergoes repeated trauma. As a result, the 
actively proliferating epithelium shows malignant transformation. 
 Banks E, et al
19
, in their study proposed that age of first birth, feeding, 
weight, diet, talc, smoking habits, few childhood viral infections and irradiation are 
considered to be various other risk factors. Another important risk factor in ovarian 
cancer is genetic alterations 
23 
. 
 
 
8 
HISTOGENESIS OF SURFACE EPITHELIAL OVARIAN TUMORS
 
K M Feeley
 
et 
 
al 
20
 proved by their study that Ovarian cyst  usually arise 
from the  ovarian surface epithelium which is the mesothelial lining of ovaries. 
Invagination of this mesothelium into the ovarian cortex stroma produces ovarian 
cyst. These inclusion cysts in the cortex will undergo epithelial metaplasia and 
progress to produce variety of surface epithelial ovarian tumors based on their 
differentiation
35
.  
S. NO TYPES OF DIFFERENTIATION TYPE OF TUMORS 
1  Fallopian tube Serous 
2 Endocervical  Mucinous 
3 Endometrial  Endometrioid 
4 Mesonephric  Clear cell 
5 Transitional   Brenner 
 
Study conducted on recent concepts in origin of serous carcinoma proved 
that high grade serous carcinomas arise from the secretory epithelial cell of 
fallopian tube which is considered as a cell of origin. 
21 
 
 
9 
PATHOGENESIS 
  Malignant epithelial ovarian cancer such as serous carcinomas commonly 
arise de novo. Mucinous, endometrioid and clear cell carcinoma usually develop 
from its benign and atypical proliferative precursor lesions
22
. Most of the serous 
carcinomas with high grade differentiation disseminate extensively into 
peritoneum during diagnosis and present in stage II & III 
23
. 
Yang DH et al 
24
, suggested that Serous carcinoma predominantly arise 
directly from surface epithelial inclusion cysts. It rarely develops from benign 
serous cystadenomas. Serous tumor usually follows rapid adenoma carcinoma 
sequence.
 
Micro papillary low grade serous carcinoma mostly arises from its 
atypical proliferative serous tumor. Thus it is considered to follow prolonged 
adenoma carcinoma sequence
22
. Recent studies on the origin of ovarian cancer 
suggested that serous intraepithelial tubal carcinoma act as a precursor for high 
grade ovarian serous carcinoma 
25
. 
Enomoto et
 
al
26
, in their study demonstrated that mucinous carcinomas 
commonly present as well differentiated tumor  and always shows areas of benign 
and borderline tumor suggesting that it develops slowly from its benign counterpart 
in a stepwise fashion.  
10 
Prowse AH et al 
27
, proved that endometriosis act as a precursor lesion for 
both endometrioid and clear cell carcinoma. Endometriosis occurs in 7-20% of 
women and it is considered as a precursor for 21% of ovarian cancers 
28, 22
. 
CLASSIFICATIONS 
WHO classification of ovarian tumors is given in annexure-II.  
Many classifications were proposed since 1940 for surface epithelial 
carcinomas. Gilks
29 
suggested a classification which helps in potential 
biological and therapeutic implications. 
1. High-grade serous, high-grade endometrioid, and undifferentiated 
carcinomas, and carcinosarcomas/malignant mixed müllerian tumors. 
2. Low-grade serous carcinomas and serous borderline tumors. 
3. Mucinous carcinomas and mucinous borderline tumors of intestinal type. 
4. Low-grade endometrioid carcinomas and endometrioid borderline 
tumors. 
5. Clear cell carcinomas. 
6. Transitional cell carcinomas. 
 
11 
Recently Kurman et al 
25
 proposed a new classification which predicts the 
behavior of the tumor and its precursors.  
Type I tumors: It is confined to the ovary during diagnosis and slow 
growing. It arises from borderline tumors which act as a precursor lesions. Low-
grade micropapillary serous carcinoma, mucinous, endometrioid and clear cell 
carcinomas and malignant Brenner tumor come under this category. 
Type  II tumors:  They grow rapidly and are highly aggressive tumors. There 
is no well defined precursor lesions identified. These include high-grade serous 
carcinoma, undifferentiated carcinoma and malignant mixed müllerian tumor. 
1988, Slotman & Rao, proposed several histopathological subgroups of 
epithelial ovarian cancers. Now the universally accepted classification is given by 
WHO committee on nomenclature and terminology of ovarian tumors 
30
.  
1. Serous tumours 
2. Mucinous tumours 
           - Intestinal type 
            - Endocervical type 
 
 
 
12 
 
3. Endometrioid 
 - Adenosarcoma 
           - Mixed mesodermal tumour 
           - Endometrioid stromal sarcoma 
4. Clear cell tumour 
5. Transitional cell tumours (including Brenner) 
6. Squamous cell tumours 
7. Mixed epithelial tumours 
8. Undifferentiated carcinoma 
  Each of these tumors is further subdivided into benign, borderline and 
malignant categories.  
Benign tumors includes cystadenoma, papillary cystadenoma, surface 
papilloma , adenofibroma, cystadenofiboroma. Malignant tumors are designated as 
adenocarcinoma, surface papillary adenocarcinoma and cysadenocarcinoma. 
Intermediate groups are considered as borderline tumors or low malignant potential  
by WHO in 1973. At present they are called as atypically proliferating epithelial 
tumors 
28, 30, 31
. 
 
13 
SEROUS TUMORS 
 Serous tumors are the commonest neoplasm of ovary which constitutes 30% 
of all ovarian tumors. Of all serous tumors, benign tumors constitutes 50%, 15% 
are borderline and invasive carcinoma constitutes 35%.
32
. It involves 5
th
 & 6
th
 
decades of life. 
Benign serous tumors include cystadenomas, adenofibromas, and 
cystadenofibromas which constitute about 25% of all benign ovarian tumors
30
.  12-
23% of cystadenomas are bilateral. It involves 4
th
 and 5
th
 decades of life. Grossly it 
is unilocular, thin walled cyst filled with straw coloured watery fluid with varying 
sizes. The inner surface is usually smooth but rarely papillary excrescences arise 
and protrude within lumen of cyst.  
Microscopically, it is lined by a type of epithelium seen in fallopian tube 
22,33
 
which is single layer of ciliated columnar cell. Mitosis and atypia is absent. Stroma 
shows edema with dense fibrovascular tissue. 15% of adenomas show psommoma 
bodies in the stroma. The adenofibroma will be highly cellular with abundant 
fibrous stroma surrounding glands and cysts.  
BORDERLINE SEROUS TUMORS (APST): 
              It constitutes about 10% of ovarian serous tumors. It involves older age 
than benign tumors. It is bilateral in 35-40% of cases. Grossly, it is cystic lesion 
14 
filled by friable cauliflower like papillary excrescences without hemorrhage and 
necrosis.  
          Microscopically, APST show hierarchical type pattern of branching
22, 28
. The 
epithelium shows extensive stratification and tufting with detachment of cell 
clusters. Epithelial buds fuses to form cribriform pattern in some foci. Mild  
nuclear atypia and mitosis seen. There is no obvious stromal invasion. The 
microinvasive foci may appear as individual cells, as clusters of cells showing 
abundant eosinophilic cytoplasm, as confluent nests forming a cribriform pattern, 
as micropapillae and macropapillae
22
. Some foci also show non hierarchical 
branching pattern with fine micropapillae arising from the central papillae 
resembling micropapillary serous carcinoma. 
MICRO PAPILLARY SEROUS CARCINOMA 
             Kurman and his group included a new category termed as micropapillary 
serous carcinoma which lies between the borderline and invasive carcinoma
34
. 
Grossly it is cystic with more papillary processes and little necrosis.  
Microscopically, it shows non hierarchical branching papillae which are thin with 
minimal fibrovascular core. Moderate nuclear atypia and increased mitosis is seen. 
It shows invasion in the form of solid nests or glandular structures surrounded by 
clear spaces
35
 
 
15 
SEROUS CARCINOMA 
50% of the malignant ovarian neoplasms are serous carcinoma. The mean 
age group is 45-65 yrs. High-grade serous carcinoma is usually bilateral and 
spreads through ovarian surface into peritoneum requiring debulking surgery
36
.  
Grossly, it is large with both solid and cystic areas. Its outer surface is 
smooth and bosselated. Cut surface of cystic cavity show soft friable papillae filled 
with serous or bloody fluid. Solid areas are pink to gray and firm. An extensive 
area of hemorrhage and necrosis is seen. 
          Microscopically, the architectural pattern of the tumor varies from complex 
papillary to solid pattern with stratification of cells, marked nuclear atypia, mitosis, 
and bizarre giant cells. Stromal invasion present. Lace like or labyrinthine pattern 
also seen focally.  Area of necrosis and hemorrhage are seen. Psommoma bodies 
are seen in 25% of serous carcinomas.  
 MUCINOUS TUMORS  
Benign Mucinous cystadenoma  constitutes about 76% of ovarian mucinous 
neoplasms. It occurs in the 3
rd
 to 6
th
 decades of life. They present as a pelvic or 
abdominal mass. Bilaterality is only 2-5%. Grossly, they are multilocular thin 
walled cysts with smooth surface. Cysts contain sticky mucoid material. Locules 
16 
are of varying size and largest of 50 cm and weight of 100 kg is reported so far
22
. 
One major cyst with many daughter cysts seen in the wall. 
 Microscopically, cysts are lined by 2 types of epithelium, Gastro intestinal 
type and Endocervical type. Intestinal type epithelium is composed of uniform tall 
columnar cells arranged in glandular and cystic structures with goblet cells or 
paneth cells. Endocervical type epithelium is associated with papillary architecture. 
Accumulation of mucin distends the cyst and cause leakage of mucin which is not 
associated with stromal reaction. 
Atypical proliferative mucinous tumors constitute 12% of all mucinous 
neoplasms. Borderline tumors are usually unilateral. Intestinal type of borderline 
tumor is more common than endocervical type.  Hart and Norris
37
 proposed that, 
borderline tumor should be considered when the atypical epithelium is less than 
four cells in thickness and as carcinoma when it is four cells or greater.   
 Grossly, they are very large, multilocular cystic mass with the mucin and 
smooth inner lining. Many show intracystic papillary processes. Microscopically, it 
shows epithelial stratification with multilayering, intraluminal tufting, atypical 
nuclear features and mitosis. There is no stromal invasion.  Endocervical type 
tumors show mucinous epithelium. APMT with microinvasion should not exceed 
5mm diameter but multiple foci of invasion can be present.    
17 
MUCINOUS CARCINOMAS  
                   Primary ovarian mucinous carcinomas are less common than the 
metastatic mucinous carcinomas. It constitutes 3.6% of ovarian epithelial 
neoplasia.  It occur in 4
th
 to 7
th
 decade of life. Bilateral tumors are mostly 
metastatic while unilateral tumors are primary. Grossly, they are                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
large  multiloculated cysts  measuring 15-20 cm . Inner surface shows firm fleshy 
white solid areas with cystic nodules. Hemorrhage and necrosis are seen.  
Microscopically, glands and cysts are arranged in complex pattern with 
irregular infolding and protrusions. Riopel ma et al,
38 
 in their study suggested that 
the  stratified epithelial lining cells which are tall picket fence cells forms 
multilayering exceeding three cell thickness with nuclear atypia, irregularly 
clumped chromatin with prominent nucleoli. Unequivocal Stromal invasion mitotic 
figures are prominent. Areas of necrosis seen.                                                                                                                                                                                                                                     
         Pseudomyxoma ovary is more commonly seen in mucinous tumors. There is 
acellular lakes of mucin entering in to ovarian stroma which is usually multifocal 
and extensive in two-third of the cases
39
. Cellular pseudomyxoma ovary is a 
condition in which pools of mucin contain clusters of epithelial cell and it is 
associated with poor prognosis. Pseudomyxoma peritonei is a progressive 
18 
condition in which mucin deposits with the epithelium undergo fibrous 
organization and get adhered to peritoneum and omentum. 
ENDOMETRIOID TUMORS 
 According to WHO, endometriod tumors are group of tumors which show 
microscopic features of typical forms of endometrial neoplasia
28, 47
. Benign and 
borderline tumors are usually rare. Endometriod carcinomas ranks second most 
common ovarian carcinoma and constitute 12-30% of all malignant surface 
epithelium ovarian tumors.  
Benign Endometrioid tumors are usually adenofibromos which is very 
uncommon. Bilaterality constitutes only 17%. Grossly, it is solid fibrous tumor, tan 
or white with small cysts resembling honeycomb appearance. Microscopically, 
Tubules and glands lined by endometrial type cells surrounded by fibrous stroma.  
 Russell and Rothe et al
40
 termed borderline tumor as “proliferating 
endometrioid tumor”. Synder et al41 and Norris have termed them into proliferative 
and low malignant potential categories. Grossly, it is unilateral measuring 6 to 10 
cm. They show solid areas predominantly with tan to white papillary excrescences. 
Microscopically, it shows increased glandular density, glandular crowding with 
lining epithelium showing stratification, mild nuclear atypia and mitosis. There is 
no stromal invasion. 
19 
 
ENDOMETRIOID CARCINOMA  
It constitutes 10 to 20% of ovarian tumors. It involves 5
th
 to 6
th
 decades of 
life.13% cases are bilateral. Patients with endometrosis for long duration usually 
have increased tendency for ovarian carcinoma. Grossly it is a solid and cystic 
tumor measuring 15 – 20 cm diameter. Areas of hemorrhage and necrosis seen. 
Some of the cysts are filled with chocolate coloured fliud.                  
Microscopically, it is characterized by glandular, papillary, villoglandular 
and cribriform pattern .There is infiltration of stroma by confluent growth. Degree  
of  atypia, stratification and solid growth pattern increases as the grade increases.      
20-50% of endometrioid carcinoma shows areas of squamous differentiation.
28
 
CLEAR CELL TUMORS         
           It is less common epithelial tumor which constitute 5 -10 % of ovarian 
carcinoma. Schiller in 1939
42
, coined the name „ mesonephroma‟ for tumors which 
had hobnail cells and glomeruloid bodies. Teilum called these glomeruloid bodies 
as Schiller-Dual bodies and recognized it to be seen in Yolk sac tumors. Scully and 
Barlow
43
 suggested that clear cell tumors arise from endometriosis. 
20 
Clear cell adenofibroma is very rare. Occurs in 5-6
th
 decades. Bilaterality is 
less than 10%. Grossly, it has smooth outer surface with cystic and solid cut 
surface. Microscopicaly, tubular glands lined by hobnail cells with minimal 
nuclear atypia and mitosis. The stroma shows fibrocollagenous tissue. Atypical 
proliferating clear cell tumor grossly appears similar to adenofibroma with soft and 
fleshy areas. Microscopically, it shows marked epithelial proliferation and atypia 
with no stromal invasion. 
Clear cell carcinoma constitutes only 2.4% of ovarian epithelial tumors.     
30-35% of clear cell carcinomas show association of endometriosis. Grossly, it is a 
large tumor measuring 10-30cm dia. Inner surface shows thick walled cyst filled 
with fleshy nodules projecting in to lumen. 
              Montag A.G et al
44
 analysed 44 cases of clear cell ca and described 3 
types of cells- clear cells, cells having eosinophilic granular cytoplasm and hobnail 
cells which are arranged in tubular, glandular and papillary pattern. Hobnail cells 
are columnar with clear to eosinophilic cytoplasm with apical nuclei that bulge into 
lumen. PAS positive eosinophilic hyaline globules are seen around the malignant 
cells. A predominant tubulocystic architectural pattern has good prognosis, but the 
cell type has no significant difference in survival. 
 
21 
BRENNER TUMOR 
 It constitutes 2-3% of all ovarian tumors. Benign tumors are more common 
than the malignant tumors. Grossly, it is circumscribed, firm, gray white solid 
tumor with foci of calcification. Microscopically, nests and cords of polygonal 
epithelial cells which resemble urothelial cells grows in a fibrous stroma. Nuclear 
groove is characteristic feature of Brenner tumor. Atypia and mitosis is absent. 
Stroma will be densely fibrous. Dystrophic calcification is seen in the hyalinised 
areas. Most of the tumors will be associated with mucinous tumors
47
. 
Borderline brenner tumor is circumscribed grey white to tan solid with 
partially cystic cavity showing papillae projecting into lumen. Microscopically, the 
intracystic papillae will be lined by transitional type of epithelium which resembles 
low grade non invasive papillary transitional cell carcinoma of urinary tract. No 
stromal invasion is seen.  
Roth L M et al
45
in their study on ovarian Brenner tumor have classified them 
as Proliferative transitional cell tumors if its epithelium is similar to grade 1 and 2 
of urothelial papillary TCC and low malignant potential tumor, if it is similar to  
grade 3 of urothelial papillary TCC. 
Malignant brenner carcinoma occurs in 50-70 years of age. Grossly, it is 
unilateral showing solid and partly cystic areas with foci of calcification. 
22 
Hemorrhage and necrosis also seen. Microscopically, it shows features similar to 
high grade transitional cell carcinoma of urinary tract. Cells are polygonal with 
amphophilic cytoplasm and pleomorphic atypical nuclei with increased mitotic 
figures. Confluent masses or irregular cords of cells invade stroma. Benign or 
atypical Brenner components should be present for diagnosis of malignant Brenner 
tumor
46
. 
UNDIFFERENTIATED CARCINOMA 
It consists of 5% ovarian cancer. It is poorly differentiated and associated 
with worse prognosis. It is usually bilateral. Grossly, it is large solid tumor with 
hemorrhage and necrosis. Microscopically, it is composed pleomorphic epithelial 
cells with variable amount of cytoplasm, vesicular nuclei with prominent nucleoli. 
Abnormal mitosis and bizarre tumor giant cells seen. 
 MOLECULAR PATHOLOGY 
 Cytogenetic study on ovarian tumors identified loss of chromosomes X, 22, 
18, 17, gain of chromosomes 12, 8 and rearrangements of 1, 3, 6, 19 chromosomes. 
There is also amplication of HER2NEU, cyclin D1, cyclin A, P21 oncogenes. 
Serous carcinomas shows positive staining for WT1 and PAX8 genes 
47 
.  
23 
Women with BRAF 1& 2 mutated gene have increased risk to develop type 
1 group of ovarian cancer. 60% of the high grade ovarian serous carcinoma shows 
P53 gene mutation
48
. KRAS mutation is more common in mucinous ovarian tumor. 
Dysregulation of the WNT signaling pathway, Micro satellite instability and Beta 
catenin mutation is seen in 40% of of endometrioid tumors. PTEN inactivation is 
seen in 20% endometriod  carcinoma 
25
. Over-expression of HNF-1beta and TGF 
beta 2 leads to Clear-cell carcinomas. The genetic alterations in transitional-cell 
carcinomas of ovary remain unknown
49
.  
IMMUNO HISTOCHEMICAL PROFILE 
In 1941, Albert Coons et al first introduced direct labeling of antibodies with 
fluorescent isocyanate. Nakane and Pierce et al in 1966, then started indirect 
labeling technique in which unlabelled antibody is followed by second antibody or 
substrate. Various methods of Immunohistochemistry includes peroxidase – 
antiperoxidase method (1970), alkaline phosphatase labeling (1971), avidin biotin 
method (1977) and two layer dextrin polymer technique (1993).
50 
Serous carcinomas will be CK7 positive and CK 20 negative. It is also 
positive for EMA, CAM 5.2, B 72.3, AE1/ AE3, CA 125 in 85% of cases. 
Mucinous carcinoma are usually CK 7 positive, they also stain for CDX-2. CK 20 
staining is variable in mucinous carcinomas. Endometrioid carcinomas will be 
24 
positive for CK 7 and CK 20. WT-I is negative which helps to differentiate it from 
endometrial carcinomas. Clear cell carcinoma show positive for CK7, 34BE12 , 
Leu M1, B72.3 and CA 125
51,22,,28.47 
      
TUMOR SPREAD AND STAGING 
Ovarian cancer spreads beyond pelvis extensively during diagnosis in 70 to 
75% of patients
7
. Local extensions, lymphatic and intra abdominal dissemination 
are the common mode of spread. Most common sites include contralateral ovary, 
peritoneal cavity, para-arotic and pelvic lymphnodes, lung and liver. Umbilical 
metastasis sometimes may be the first manifestation termed as Sister Joseph 
nodule. Borderline tumors have a tendency for both invasive and non invasive 
peritoneal implants 
47
. 
 FIGO staging is the most powerful predictor of prognosis
32, 28
. TNM 
systems are based on post operative pathological staging. FIGO Staging is given in 
annexure III. 
PROGNOSIS 
            The overall prognosis of ovarian carcinoma remains poor due to its rapid 
growth and absence of early symptoms. Hence majority of the patients present in 
advanced stage during diagnosis. The survival rate is 35% at 5 yrs, 28% at 10yrs 
and only 15% at 25 yrs.  
25 
          Chan J.K et al
52 
proposed various factors like age, FIGO staging, tumor 
histological type, grade, ascites, fluid cytology, CA125 level, presence of residual 
disease which all have influence on the prognosis of ovarian tumors. 
In 2008, Oldenhuis et al
53
, suggested that molecular biological factors also 
predicts the prognosis and have therapeutics values. P53, Her2neu over expression 
and BRCA1 mutation affect the survival of the patients. 
 Patients of age older than 60yrs and advanced stage were associated with 
poor prognosis
54
. Patients with stage 1 disease have better survival of 90%. 
Patients with stage IV have poor prognosis and survival is only 10-20% because of 
wide spread metastatic disease. Lee-jones L
12
 analysed epithelial tumors and 
demonstrated the 5 yr survival rate in various stages of disease. In Stage -I disease 
survival rate is 82% and in Stage-II reduces to 64%, Stage III – 38%, in stage IV it 
is only 14%. Younger patients have better prognosis. This is because they present 
at early stage and disease is lower grade in these young women
55
. Positive 
peritoneal cytology usually indicates the presence of extra ovarian disease. Serous 
and endometrioid carcinomas are more often show positive for ascitic fluid 
cytology. High grade ovarian tumors are more positive than low-grade tumors.
56
 
 
26 
Tumor grade also affects the prognosis. As already described, Silverburg 
and colleagues
9 
proposed universal grading system which  pointed out that grading 
also helps in predicting response of the tumor to chemotherapy. Serous 
Carcinomas have worst prognosis. Micro papillary serous tumor shows increased 
recurrence of invasive carcinoma and tumor deaths. Mucinous carcinomas have 
excellent prognosis. The prognosis of endometrioid carcinoma is better than the 
serous or mucinous carcinoma. Clear cell carcinoma have poor prognosis and they 
always show resistant to chemotherapy
44
. 
Austin and Norris
46
 pointed out that the prognosis of malignant Brenner 
tumors with an associated benign component is better than transitional cell 
carcinomas (non-Brenner type). Tumors showing aneuploidy generally present as 
high grade and they behave more aggressively than the diploid tumors. CA-125 
serum markers are more useful in the initial evaluation of these patients and in the 
follow-up to diagnose the recurrent disease. Thus it is considered to be an 
independent prognostic factor. Overexpression of P53 and HER2NEU has been 
suggested to be a marker of poor prognosis in most of the studies
47, 53
. 
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HER 2 NEU  
          HER2 neu (Human Epidermal growth factor Receptor 2) also known as 
cerbB2 is an oncogene belongs to EGFR family
57
. It encodes a 185 kDa 
transmembrane glycoprotein with tyrosine kinase activity.  
The proto-oncogene is encoded in the long arm of chromosome 17(17q11.2 – 12 ) 
gene 
22, 57
. HER-2/neu gene contains a cysteine rich extracellular ligand binding 
domain, a hydrophobic  
membrane spanning region, and an intracellular tyrosine kinase domain. These 
domains activates multiple signaling pathways like mitogen activated Protein 
kinase, Phospholipase C, signal transducer  and activator of transcription ( STAT) 
signaling  through ERBB family of receptors thereby regulating cell proliferation , 
differentiation  and inhibits apoptosis. 
Padhy L.C et al
58 
in 1982   identified this oncogene which was associated 
with the development of neuroblastomas in rats exposed to ethylnitrosourea in 
utero  due to point mutation on the membrane spanning region. In humans, only 
HER-2/neu amplification and overexpression rather than point mutation produces 
malignant tumors
54, 58
. 
           Several studies on breast carcinomas have suggested that overexpression of 
Her2neu occurs in 15-40% of cancers and is associated with poor survival
58
.   
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Amplification and overexpression is also seen in other human malignancies 
including ovarian cancer, stomach and uterine cancer. Her 2 neu positivity in 
endometrial carcinomas indicates aggressive behavior due to its extensive 
metastasis. The prognostic significance of Her2neu overexpresion in surface 
epithelial tumors remains controversial.
59,60,61,62, 
                                                                       
Her2neu is negative in normal ovary. Ovarian carcinoma shows Her2neu 
positivity in one third of cases. Amplification and over- expression of ERBB2 gene 
 
occurs in 30% of ovarian cancer
8
. It is associated with increased disease recurrence 
and worse prognosis. Her2neu protein overexpression is studied by IHC and gene 
amplification by FISH.  
 FISH is used as secondary test in equivocal 2+ IHC categories to clarify 
HER2 status of these cases. Other methods of HER 2 testing techniques include 
Chromogenic Insitu Hybridization, PCR, ELISA and Southern blotting. 
  Trastuzumab is a humanized monoclonal antibody that acts by targeting 
the HER2 extracellular domain and thereby inhibits proliferation of Her2neu 
positive tumor cell. The extracellular domain of HER 2 is shed from the surface of 
tumor cells and enters the circulation. Hence measurement of this serum Her2 is 
also used in predicting response to herceptin therapy. Nec vax is a newly identified  
29 
Peptide based immunotherapy that directs „ killer‟ T cell  to target and destroy 
neoplastic cells expressing HER 2 which is under trial. 
 Her 2 neu in ovarian tumors is studied not only as prognostic marker but 
also for herceptin treatment. Her 2 neu overexpression is associated with more 
aggressive behavior and with poor survival
58,8
. Some study shows that it has no 
prognostic significance. Further studies on Her 2 overexpression also show that it 
is associated with chemotherapy resistance
22
. Hence this study is done to analyze 
the overexpression of Her 2 neu in ovarian carcinoma and its association with more 
aggressive behavior and poor survival. 
P53 
P53 is a tumor suppressor protein which encodes T P53 gene and is located 
in short arm of Ch – 17 (17 p 13.1)62. This gene encodes 53 kDa phosphoprotein 
which act as a transcription factor. It  regulates cell cycle and function as a tumor 
suppressor gene by preventing cancer. Hence P53 is also known as “the guardian 
of genome”63. It plays a role in apoptosis, genomic stability and inhibits 
angiogenesis. It induces growth arrest and activates DNA repair proteins when it is 
damaged.
64 
 P53 down regulate cell cycle and act as cell cycle checkpoints. P53 is a 
transcription factor which on DNA damage is activated and induces transcription 
30 
of P21, a cyclin dependent kinase inhibitor to arrests DNA synthesis and thus 
cause cell cycle arrest. Certain mutagens such as chemical, radiation, viruses cause 
damage to p53 gene. Loss of functional p53 leads to variety of malignancies due to 
inability of cells to undergo apoptosis and show resistance to chemotherapy. 
Mutation of p53 gene is the most common molecular genetics change 
associated with various cancers including ovarian cancers. Inherited T P53 gene 
mutation cause Li- fraumeni syndrome. P53 inactivation also leads to cervical 
cancer. P53 overexpression is associated with poor prognosis in breast cancer, lung 
and colorectal carcinomas.
65.66,67.
 P53 gene mutation and overexpression is seen in 
50 to 60% of ovarian cancer
68
. Studies on Atypical proliferating serous and 
mucinous tumor also suggested that it shows P53 mutation. Mutation in P53 
usually occurs in DNA binding domain.  
Immunohistochemical assay is done to detect overexpression of p53 protein. 
50% of ovarian carcinomas shows staining for p53 with strong positive nuclear 
staining is seen in 30% to 50% of serous carcinomas. Benign and borderline serous 
tumors are usually p53-negative.  
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Studies by the Gynecologic Oncology Group have shown that 
overexpression of p53 is due to missense mutation and it is associated with poor 
prognosis in advanced ovarian cancers
69
. Advanced stage disease shows increased 
frequency of overexpression of about 40% to 60% than the stage I disease which is 
only 10% to 20%. This higher frequency of p53 overexpression in advanced stage 
patients indicates that it is a late event in ovarian carcinogenesis.  
 Eltabbakh GH, et al have shown that p53 plays a major role in inducing 
apoptosis following chemotherapy-induced DNA damage. Some in vitro ovarian 
cancer studies have demonstrated that loss of p53 is responsible for 
chemoresistance
70
. Further studies on this functionally inactive p53 also show that 
it behaves aggressively due to inability to repair mutated genes. Additional studies 
are under study to define the roles of p53 in regulating therapeutic responsiveness 
and patient outcome. 
Sheridan  E et al
71
 in their study on P53 mutation and prognostic 
significance have shown that P53 overexpression is seen in tumors with increasing 
stage and grade suggesting that it has poor prognosis. 
 Reles et al
72
, suggested controversial thought that neither P53 mutation nor 
expression in ovarian cancer was associated with poor survival of the patients  
32 
Various commonly used methods to detect the alteration in P53 gene are 
IHC, PCR-SSCP, Flow Cytometry and genomic sequencing. In IHC, brown 
staining of the nuclei is considered as positive. 
In this study, P53 overexpression detected by IHC on surface epithelial 
ovarian tumors and its prognostic significance is analysed. 
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MATERIALS AND METHODS 
 
 This study is a retrospective descriptive study of malignant surface 
epithelial ovarian tumors conducted in the Madras Medical College- Institute of 
Obstetrics & Gynaecology, Egmore & Institute of Social Obstetrics and Kasthurbai 
Gandhi Hospital, Triplicane during the period between Jan 2008 and Oct 2012.   
SOURCE OF DATA 
All cases of malignant surface epithelial ovarian tumors reported in 
hysterectomy and salphingo ophorectomy specimen received in the Institute of 
Obstetrics & Gynaecology, Egmore & Institute of Social Obstetrics and Kasthurbai 
Gandhi Hospital, Triplicane between Jan 2008 to Oct 2012. A total of 850 ovarian 
tumor specimens were received during this period. Out of these, 162 cases were 
malignant surface epithelial ovarian tumors. 
INCLUSION CRITERIA 
     All Malignant Surface Epithelial Ovarian Tumors reported in the study period. 
EXCLUSION CRITERIA 
 Non neoplastic lesions and benign tumors of ovary. 
 Other ovarian tumors with surface epithelial components. 
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METHOD OF DATA COLLECTION 
      Detailed history of the cases regarding age, site of the tumor, type of 
procedure, history of neo adjuvant therapy, details of gross characteristics such as 
tumor size, soild, cystic papillary areas, CA125 Level were obtained for all the 162  
cases reported during the period from Surgical Pathology records. Freshly cut and 
Hematoxylin Eosin stained 4 µ thick sections of the paraffin tissue blocks of 
specimens were reviewed and their histological subtypes (serous, mucinous, 
endometrioid, clearcell, Brenner) and grade (well, moderate, poorly differentiated) 
and stage were studied. They are further evaluated for the presence of ascites, 
involment of omentum by tumor cells. 50 cases of all subtypes and grade from 
surface epithelial ovarian carcinoma were randomly selected from the total cases 
and their representative formalin fixed paraffin embedded tissue samples with 
sufficient tumor available were subjected to IHC for a panel of 2 markers. The 
results were recorded with photographs. Follow up data of these patients regarding 
the adjuvant therapy, dose, duration, recurrence, survival data were obtained from 
Medical Records Section of Department of Oncology. 
IMMUNOHISTOCHEMICAL EVALUATION                       
       Immuohistochemical analysis of a 2 markers , Human epidermal growth factor 
receptor 2 (Her 2 neu) and P 53 were done in paraffin embedded tissue samples  
35 
Using supersentive polymer HRP system based on non biotin polymeric 
technology.  
4 µ thick sections from selected formalin fixed paraffin embedded tissue 
samples were transferred onto gelatin coated slides. Heat induced antigen retrieval 
was done. The antigen is bound with rabbit monoclonal antibody against Her2neu 
protein and mouse monoclonal antibody against p53 protein   and then detected by 
the addition of secondary antibody conjugated with horse radish peroxidase-
polymer and Diaminobenzidinesubstrate. The step by step procedure of 
Immunohistochemistry is given in Annexure IV. 
ANTIGEN VENDOR SPECIES DILUTION POSITIVE 
CONTROL 
Her 2 neu BIOGENEX Rabbit Ready to use Breast cancer 
P53 BIOGENEX Mouse Ready to use Breast cancer 
 
INTERPRETATION & SCORING SYSTEM 
The immunohistochemically stained slides were analyzed for the presence of 
reaction, cellular localization (nuclear/cytoplasmic/membranous/combinations), 
percentage of cells stained and intensity of reaction. Nuclear staining was assessed 
for P53 and membranous staining for Her2neu. P53 was scored based on 
percentage of tumor cells showing positive nuclear staining. >10% of tumor cells 
36 
showing immunonuclear staining were considered as positive. Positive staining in 
less than 10% of cells were taken as negative. Ellis and Wolff recommendations
73
 
were used to assess Her2 neu positivity. An estimation of more than 10 % of tumor 
cells with cytoplasmic staining was considered as positive reaction for Her 2 neu. 
In this study, Her 2 neu score of 0 and 1+ were considered as negative and score 
2+ equivocal and 3+ were considered as positive. 
STATISTICAL ANALYSIS 
The statistical analysis is performed using statistical package for social 
science software version 11.5. Correlation between Her2neu and P53 
overexpression and clinicopathological prognostic factors such as age, tumor size, 
CA 125 level, subtypes, grade, and stage in these patients was analyzed using 
Pearson chi square test. P53 and Her 2 neu results were studied as positive or 
negative for the purpose of statistical analysis.   
SURVIVAL ANALYSIS 
All the patients who underwent surgery were given chemotherapy. 6 courses 
of cisplatin and cyclophosphamide every 21 days were given. Then the patients 
were followed up until the period of study. Survival data were collected from the 
date of initiation of treatment until death from any cause. Median follow up of 15 
months were done. Surviving patient‟s data were calculated at the date of last visit. 
37 
Disease progression was estimated from the date of treatment initiation until the 
date of progression or death without documented relapse. Results were interpreted 
as those survived and not survived for the purpose of statistical analysis. Relative 
risk (RR) and their 95% confidence interval were calculated. Only p values less 
than 0.05 was reported as significant.  
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OBSERVATION AND RESULTS 
In the study period of 5 yrs from 2008 to 2012, a total of 850 ovarian 
specimens were received in the Institute of Pathology, Madras Medical College 
Institute of Obstetrics & Gynaecology, Egmore & Institute of Social Obstetrics  
and Kasthurbai Gandhi Hospital, Triplicane for histological examination. Of these 
surface epithelial ovarian cancer accounted for 638 cases with a percentage of 75.1. 
The total number of benign, borderline, malignant cases was 441, 35 and 162 
respectively. Thus the distribution of benign tumors was 69.1%, borderline tumors 
5.5 % and malignant tumors were 25.4 % among the surface epithelial ovarian 
cancer specimens. Serous carcinoma constitutes 55.6%, mucinous 17.9%, 
endometrioid 21%, clear cell 3.7% and mixed tumors constitutes 1.9% of all 
malignant surface epithelial ovarian tumors. 
Ovarian cancers had a peak incidence in the age group of 41-50 years. The 
Youngest age of presentation of ovarian cancer was 21 years in this study, with 
mean age of 47 yrs. 
Among the 162 cases, 68 cases(42%) were reported in age of 41-50yrs and 
48 cases(29.6%) were reported in age of 51-60 yrs. Only 4.9% of the cases 
presented in the 2
nd
 to 3
rd
 decades of life.  (Table 1) 
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TABLE 1: AGE WISE DISTRIBUTION OF EPITHELIAL OVARIAN 
CANCERS 
AGE FREQUENCY PERCENTAGE MEAN 
21-30 8 4.9  
 
 
47.7 
31-40 28 17.3 
41-50 68 42.0 
51-60 48 29.6 
61-70 10 6.2 
TOTAL 162 100.0 
 
Among the 162 cases, 71 cases (43.8%) presented with right ovarian mass, 
48 cases (29.6%) had left ovarian mass and 43 cases (26.5%) had bilateral ovarian 
mass. (Table 2 and Chart 1) 
TABLE 2: DISTRIBUTION OF SITE OF INVOLVEMENT IN OVARIAN 
CARCINOMA 
SITE FREQUENCY PERCENTAGE. 
Left 71 43.8 
Right 48 29.6 
Bilateral 43 26.5 
Total 162 100.0 
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 62 cases (68.89%) of the serous carcinomas, 25 cases (86.2 %) of mucinous 
carcinomas and 25 cases (73.5%) of  endometrioid carcinomas were unilateral at 
the time of presentation .  83.3% of Clear cell carcinoma presented as unilateral 
tumor. Bilaterality in serous and mixed tumours was 28 cases (31.11%) and one 
case (33.33%) respectively. In mucinous carcinoma only 13% of cases were 
bilateral. (Table-3) 
 
TABLE 3: DISTRIBUTION OF SITE BASED ON HISTOLOGICAL TYPES 
 
 
 
TUMORS 
 
UNILATERAL 
 
BILATERAL 
 
FREQUENCY 
 
PERCENTAGE 
 
FREQUENCY 
 
PERCENTAGE 
Serous 62 68.89 28 31.11 
Mucinous 25 86.2 4 13.8 
Endometrioid 25 73.5 9 26.5 
Clearcell 5 83.33 1 16.67 
Mixed 2 66.67 1 33.33 
Total 119 75.71 43 24.29 
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Epithelial carcinoma can be grouped into following types according to their 
gross morphology. Among the 162 cases, 48(29.6%) of cases were both solid and 
cystic, 35(21.6) of cases were purely solid tumors. 30 cases (18.5%) presented with 
papillary excrescence in solid tumors. 18 cases (11.1%) showed multiloculated 
cyst. 7cases (4.3%) were purely cystic. 10 cases of cystic and 14 cases of solid and 
cystic tumors also presented with papillary excrescence. (Table 4 and Chart 2) 
TABLE 4: DISTRIBUTION OF OVARIAN CARCINOMA BASED ON 
GROSS MORPHOLOGY 
GROSS FREQUENCY PERCENTAGE 
Solid/ Cystic 48 29.6 
Solid 35 21.6 
Solid, Papillary 30 18.5 
Multiloculated cystic 18 11.1 
Solid/ Cystic, Papillary 14 8.6 
Cystic, Papillary 10 6.2 
Cystic 7 4.3 
Total 162 100.0 
 
 Ovarian tumor distribution according to their histological subtypes is 
shown in   the   Table-5. 55.6% of serous carcinoma, 7.9% of mucinous, 21% of 
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endometrioid, 3.7% of  clear cell type and 1.9% of mixed type tumor was 
observed. (Table 5 and Chart 3) 
TABLE 5: DISTRIBUTIONS OF HISTOLOGICAL SUBTYPES OF 
OVARIAN CANCERS 
HISTOLOGICAL TYPE FREQUENCY PERCENTAGE 
Serous 90 55.6 
Endometrioid 34 21.0 
Mucinous 29 17.9 
Clear cell  6 3.7 
Mixed tumors 3 1.9 
Total 162 100.0 
 
 
83.3% of the tumor with solid papillary excrescences was reported as serous 
carcinomas. 78.6 % of the tumor showing solid cystic papillary excrescences 
belonged to serous carcinoma. 77.8% of the tumors with multiloculated cyst were 
reported as mucinous carcinomas. 57% of the purely cystic tumor was mucinous 
carcinomas. 34% of the purely solid tumors belonged to endometrioid carcinomas. 
Clear cell carcinoma showed varying gross morphology as shown in the Table 6. 
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TABLE 6: DISTRIBUTION OF HISTOLOGICAL SUBTYPES BASED ON 
THEIR GROSS MORPHOLOGY 
 
Among the study sample, 85 cases of carcinomas were less than 10cm, 67 
cases had size between 10-20 cm, and 10 cases showed tumor size of more than 
20cm. The size of the tumor ranges from 5 cm to 34 cm. The mean size of the 
tumor  is 10cm. (Table 7) 
TABLE 7: DISTRIBUTION OF SIZE IN OVARIAN CARCINOMA 
SIZE NO OF CASES FREQUENCY MEAN 
<10 cm 85 52.5  
10.99 
 
10-20 cm 67 41.4 
>20 cm 10 6.1 
GROSS 
MORPHOLOGY 
SEROUS 
N (%) 
MUCINOUS 
N (%) 
ENDOMETRIOID 
N(%) 
CLEAR 
CELL 
N (%) 
MIXED      
N (%) 
Solid with papillary  25 (83.3) 1(3.3) 2(6.7) 2 (6.7) - 
Solid cystic with 
papillary  
11 (78.60) 1(7.1) 2(14.3) - - 
Pure solid 20 (57.1) - 12(34.3) 2(5.7) 1(2.9) 
Cystic with papillary  5 (50) 2(20) 3(30)   
Solid with cystic 23 (47.9) 7(14.6) 15(31.3) 2  (4.2) 1(2.1) 
Pure cystic 2 (28.6) 4 (57.1) - - 1(14.3) 
Multiloculated cystic 4 (22.2) 14 (77.8) - - - 
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Among the 85 cases with size less than 10cm, 60 cases (70.6%) were serous 
type. Out of 10 cases with size more than 20 cm, 6 cases (60%) were mucinous 
carcinomas. Other carcinomas were in size between 11-20 cm. (Table 8) 
TABLE 8: DISTRIBUTION OF SIZE BASED ON HISTOLOGICAL SUBTYPES 
 < 10 cm 
N (%) 
11-20 cm 
N (%) 
 
>20 cm 
 N (%) 
Seruous 60(70.6) 27 (40.3) 3(30) 
Mucinous 3 (3.5) 20(29.9) 6(60) 
Endometriod 15(17.7) 18(26.9) 1(10) 
Clearcell 5(5.9) 1(1.5) - 
Mixed 2(2.4) 1(1.5) - 
Total 85(100%) 67(100%) 10(100%) 
 
Ovarian carcinomas were graded according to Silverberg
‟
s grading system. 
In this study 70 cases (43.2) were in grade-I, 48 cases (29.6%) were in grade II and 
44 cases (27.2%) were in grade III. (Table 9 and Chart 4) 
TABLE 9: DISTRIBUTION OF GRADE IN OVARIAN CARCINOMAS 
 
GRADE FREQUENCY PERCENTAGE 
I 70 43.2 
II 48 29.6 
III 44 27.2 
Total 162 100.0 
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Out of 90 cases serous carcinomas, 34cases (37.7%) were in grade II, 28 
cases were in grade I and III. Among the 29 mucinous carcinomas, 25 cases 
(86.2%) were in grade I differentiation. 50% of endometrioid carcinomas were 
presented as grade I tumors. All 6 cases of clear cell carcinoma (100%) were in 
grade III. (Table 10) 
TABLE 10: DISTRIBUTION OF GRADE BASED ON HISTOLOGICAL TYPES 
TUMORS GRADE-1 GRADE-II GRADE-III 
Serous n= (90) 28 (31.11%) 34 (37.77%) 28 (31.11%) 
Mucinous n=(29) 25 (86.2%) 2 (6.9%) 2 (6.9%) 
Endometrioid n=(34) 17 (50%) 11 (32.35%) 6 (17.65%) 
Clear cell n=(6) - - 6 (100%) 
Mixed n=(3) - 1 (33.33%) 2 (66.67%) 
Total 70 48 44 
 
Among the study sample, 70 cases (43.2%) presented in early stage (stage I 
& II) and 92 cases (56.8%) presented in late stage (III&IV). (Table 11 and Chart 5) 
TABLE 11: DISTRIBUTION OF STAGE IN OVARIAN CARCINOMA 
STAGE FREQUENCY PERCENTAGE 
Late (Stage III & IV) 92 56.8 
Early ( Stage  I &II) 70 43.2 
Total 162 100.0 
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Among the various histological types, 63cases (70%) serous carcinomas 
were observed in late stage, 66.7% of clear cell carcinoma in late stage. Increased 
frequency of cases in early stage was observed in 62.1% of mucinous and 64.7% of 
endometrioid carcinomas. (Table 12) 
 
TABLE 12: DISTRIBUTION OF STAGE WITH HISTOLOGICAL TYPES 
 SEROUS MUCINOUS ENDOMETRIOID CLEAR 
CELL 
MIXED 
Late 63(70%) 11(37.9) 12(35.3) 4(66.7) 2(66.7) 
Early 27(30%) 18(62.1) 22(64.7) 2(33.3) 1(33.3) 
Total 90(100%) 29(100%) 34(100%) 6(100%) 3(100%) 
  
             In this study, 126 cases (77.8%) showed the presence of ascites and 36 
cases (22.2%) did not have ascites.(Table 13) 
TABLE 13: DISTRIBUTION OF OVARIAN CARCINOMA BASED ON  
PRESENCE OF ASCITES 
ASCITES FREQUENCY PERCENTAGE 
Present 126 77.8 
Absent 36 22.2 
Total 162 100.0 
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6 cases (100%) of clear cell carcinomas and mixed carcinomas showed the 
presence of ascites followed by 77cases (85.5%) of serous carcinomas. Patients 
with other histological subtypes also had ascites (61-65%). (Table 14) 
TABLE-14:DISTRIBUTION OF PRESENCE OF ASCITES WITH 
HISTOLOGICAL SUBTYPE. 
TUMOR 
TYPE(N) 
PRESENCE 
OF ASCITES 
 
PERCENTAGE 
Clear cell ca( 6) 6 100 
Mixed type(3) 3 100 
Serous(90) 77 85.5 
Mucinous(29) 19 65.51 
Endometrioid(34) 21 61.76 
TOTAL 126 77.8 
 
Among the 162 cases, 80 cases (49.4%) showed omentum deposits and 82 
cases (50.6%) do not show omental deposits. (Table 15) 
TABLE 15: DISTRIBUTION BASED ON OMENTUM INVOLVEMENT 
 
 
OMENTUM FREQUENCY PERCENTAGE 
Negative 82 50.6 
Positive 80 49.4 
Total 162 100.0 
48 
 
 In the present study, 55 cases (61.1%) of serous carcinoma had omentum 
deposits, 10 cases of mucinous (34.5%) and 10 cases of endometrioid (29.4%) 
carcinoma showed carcinomatous deposits. Out of 6 cases of clear cell carcinoma 4 
cases (66.6%) had omentum deposits. (Table 16) 
 
TABLE 16: DISTRIBUTION OF OMENTUM INVOLVEMENT WITH 
HISTOLOGICAL TYPE 
SUBTYPES FREQUENCY PERCENTAGE 
Clearcell 4 66.7 
Serous 55 61.1 
Mucinous 10 34.5 
Mixed 1 33.3 
Endometriod 10 29.4 
 
 
RESULTS OF IMMUNOHISTOCHEMICAL STUDIES 
Of the total 162 cases, 50 cases of varying types, grade and stage were 
selected in a random manner and subjected to immunohistochemical analysis with 
a panel of 2 markers – P53 and Her2neu. Prognosis and survival data were  
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analyzed on these 50 patients. The age of the patients ranged between 26 and 70 
with a mean of 49 yrs. There were 9 cases (18%) below 40 years of age and   
cases (82%) more than 40 years. 15 cases (30%) were located in left ovary, 23 
cases (46%) in right ovary and 12 cases (24%) were bil‟[ateral tumor.  Grossly, 18 
cases (36%) showed both solid and cystic areas, 15 cases (30%) solid with 
papillary excrescences, 6cases (12%) purely solid, 6cases (12%) with solid cystic 
with papillary excrescences and 4 cases (8%) presented as multiloculated cyst. The 
tumor ranged in size from 5 cm to 34cm with the median size of 10cm. There were 
28cases(56%) with tumor size less than 10cm, 14cases (28%) with tumor size 
between 10 to 20cm and 8 cases(16%) were in size more than 20cm. 
Histologically, 29 cases (58%)  belonged to serous type, 12 cases(24%) belonged 
to endometrioid,  6 cases(12%) were mucinous, and 3 cases(6%) belonged to clear 
cell type. 21 cases(42%) were well differentiated carcinomas, 13 cases (26%) 
showed moderate differentiation and 16 cases(32%) were poorly differentiated 
carcinomas. 33 cases(66%)  belonged to advanced stage, 17cases(34%) were in 
early stage. In this sudy group, 38 cases (76%) had ascites and 12 cases (24%) did 
not have ascites. Omental involvement was seen in 30 cases (60%) of patients and 
it was absent in 20 cases (40%). 
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TABLE 17: DISTRIBUTION OF OVARIAN CARCINOMA AMONG 
THE VARIOUS CLINICOPATHOLOGICAL GROUPS FOR THE IHC 
STUDY (50 CASES) 
 
CLINICOPATHOLOGICAL FACTOR NO OF CASES 
 
AGE >40 yrs 39(78%) 
<40 yrs 11(22%) 
SITE Right 23(46%) 
Left 15(30) 
Bilateral 12(24) 
GROSS Solid/ Cystic 18(36%) 
Solid, papillary 15(30%) 
Solid 6(12%) 
Solid/ Cystic, papillary 6(12%) 
Multiloculated 4(8%) 
Cystic, papillary 1(2%) 
SIZE <10 cm 28(56%) 
10-20 cm 14(28%) 
>20 cm 8(16%) 
STAGE Late 33(66%) 
Early 17(34%) 
GRADE G-I 21(42%) 
G-II 13(26%) 
G-III 16(32%) 
TYPE Papillary serous ca 29(58%) 
Endometrioid ca 12(24%) 
Mucinous ca 6(12%) 
Clear cell carcinoma 3(6%) 
ASCITES Present 38(76%) 
Absent 12(24%) 
OMENTAL 
DEPOSITS 
Present 30(60%) 
Absent 20(40%) 
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In this study, out of 50 cases, 24 cases (48%) expressed positivity to P53 and 
26 cases (52%) were negative for P53.Only 2 cases (4%) expressed positive to Her 
2 neu (3+) and 48  cases(96%) were negative for Her 2 neu expression.( Table 18) 
TABLE 18: DISTRIBUTION OF P53 EXPRESSION AND HER 2 NEU IN 
OVARIAN CARCINOMA 
 
IHC P53 HER2NEU 
RESULTS POS NEG POS NEG 
 24(48%) 26(52%) 2(4%) 48(96%) 
TOTAL 50(100%) 50(100%) 
 
 
CORRELATION OF P53 WITH VARIOUS CLINICO- PATHOLOGICAL 
FACTORS 
P53 positivity was noted in 45.5% patients with age less than 40 and in 
48.7% patients with age more than 40yrs. The mean age of patient expressed P53 
positivity was 49 yrs. (Table 19) 
TABLE 19: CORRELATION OF AGE WITH P53 EXPRESSION 
P53 
AGE 
N MEAN 
STD. 
DEVIATION 
P-VALUE 
<40yrs >40yrs 
Positive 5 19 24 49.13 9.799 
0.351 
Negative 6 20 26 46.58 9.347 
52 
In this study, P53 positivity was observed in 50% of bilateral ovarian 
carcinomas, 66.7% of patients of left ovary and 34.8% of patients of right ovarian 
carcinoma. (Table 20) 
TABLE 20: CORRELATION OF TUMOUR SITE WITH P53 EXPRESSION 
 
VARIABLES 
P53 TOTAL 
 P-VALUE POSITIVE NEGATIVE 
N % N % N % 
SITE 
Left 10 66.7 5 33.3 15 100.0 
0.157 Right 8 34.8 15 65.2 23 100.0 
Bilateral 6 50.0 6 50.0 12 100.0 
 Total 24 48.0 26 52.0 50 100.0  
 
Among the various gross types, P53 positivity is seen in 66.7% of tumor 
with solid & papillary excrescences, 38.9% of solid and cystic, 33.3% of solid 
cystic with papillary excrescences, 25% of multiloculated cystic and 100% of  
cystic papillary morphology. (Table 21) 
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TABLE 21: CORRELATION OF GROSS MORPHOLOGY WITH P53 
POSITIVITY 
VARIABLES 
P53 TOTAL 
 P-VALUE POSITIVE NEGATIVE 
N % N % N % 
GROSS 
Solid/ Cystic 7 38.9 11 61.1 18 100.0 
0.430 
Solid, papillary 10 66.7 5 33.3 15 100.0 
Solid/ Cystic, papillary 2 33.3 4 66.7 6 100.0 
Solid 3 50.0 3 50.0 6 100.0 
Multiloculated 1 25.0 3 75.0 4 100.0 
Cystic, papillary 1 100.0 0 0.0 1 100.0 
 Total 24 48.0 26 52.0 50 100.0  
 
 
In this study, 53.6% of the tumor size less than 10cm expressed positivity, 
50% of the tumor size 10-20 cm and 25% of the tumor size more than 20cm was 
positive for P53.(Table 22) 
 
54 
TABLE 22: CORRELATION OF SIZE WITH P53 POSITIVITY 
P53 
SIZE 
MEAN 
STD. 
DEVIATION 
P-VALUE 
<10cm 10-20cm >20cm 
Positive 15(53.6%) 7(50%) 2(25%) 9.521 4.6097 
0.173 
Negative 13(46.4%) 7(50%) 6(75%) 12.135 8.3085 
 
According to FIGO stage, 63.6% of patients with late stage (III & IV) 
expressed P53 positivity and only 17.6% of patients presented in early stage 
showed P53 positivity.( Table 23 and Chart 6)  
TABLE 23: CORRELATION OF FIGO STAGE WITH P53 POSITIVITY 
VARIABLES 
P53 TOTAL 
 P-VALUE POSITIVE NEGATIVE 
N % N % N % 
STAGE 
LATE 21 63.6 12 36.4 33 100.0 
0.002 
EARLY 3 17.6 14 82.4 17 100.0 
 TOTAL 24 48.0 26 52.0 50 100.0  
 
Among the histological types, 66.7% of clear cell carcinoma expressed P53 
positivity, 55.2% of serous carcinoma, 33.3% of both endometriod and mucinous 
carcinoma showed P53 positivity. (Table 24) 
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TABLE-24: CORRELATION OF HISTOLOGICAL TYPES WITH P53 
POSITIVITY 
VARIABLES 
P53 TOTAL 
 P-VALUE POSITIVE NEGATIVE 
N % N % N % 
HISTOLOGICAL   
TYPE 
Clear Cell 2 66.7 1 33.3 3 100.0 
0.512 
Serous 16 55.2 13 44.8 29 100.0 
Endometrioid 4 33.3 8 66.7 12 100.0 
Mucinous 2 33.3 4 66.7 6 100.0 
 
In the present study, P53 positivity was observed in increased frequency of 
cases with high grade tumors. 23.8% of well differentiated carcinomas(G1), 46.2% 
of moderately differentiated carcinomas(G2) and 81.3% of poorly differentiated 
carcinomas(G3) showed positivity for P53. (Table 25 and Chart 7) 
TABLE 25: CORRELATION OF GRADE WITH P53 POSITIVITY 
VARIABLES 
P53 TOTAL 
 P-VALUE POSITIVE NEGATIVE 
N % N % N % 
GRADE 
III 13 81.3 3 18.8 16 100.0 
0.002 
II 6 46.2 7 53.8 13 100.0 
I 5 23.8 16 76.2 21 100.0 
Total 24 48.0 26 52.0 50 100.0 
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22 cases (57.9%) presented with ascites and 2 cases (16.7%) without ascites 
had showed P53 positivity. (Table 26) 
TABLE 26: CORRELATION OF ASCITES WITH P53 POSITIVITY 
VARIABLES 
P53 TOTAL 
 P-VALUE POSITIVE NEGATIVE 
N % N % N % 
ASCITIS 
Positive 22 57.9 16 42.1 38 100.0 
0.013 Negative 2 16.7 10 83.3 12 100.0 
Total 24 48.0 26 52.0 50 100.0 
 
In the present study, expression of P53 positivity is seen in 63.3% of cases 
with omentum involvement, 25% of patients without omental deposits were 
observed. (Table 27) 
TABLE 27: CORRELATION OF OMENTUM INVOLVEMENT WITH P53 
POSITIVITY 
VARIABLES 
P53 TOTAL 
 P-VALUE POSITIVE NEGATIVE 
N % N % N % 
OMENTUM 
Positive 19 63.3 11 36.7 30 100.0 
0.008 Negative 5 25.0 15 75.0 20 100.0 
Total 24 48.0 26 52.0 50 100.0 
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In this study, the mean CA125 level with P53 positive cases is 371.33 IU 
and for negative cases mean is 497.221 IU. (Table-28) 
TABLE 28: CORRELATION OF CA125 LEVEL WITH  P53 POSITIVITY 
VARIABLES P53 N MEAN 
STD. 
DEVIATION 
P-VALUE 
CA125 
Positive 24 371.33 775.364 
0.714 
Negative 26 497.221 1497.65 
 
CORRELATION OF HER 2 NEU WITH VARIOUS CLINICO 
PATHOLOGICAL FACTORS 
Her2neu positivity is seen in 9% of cases with age less than 40 yrs and 2.6% 
of cases with age above 40 yrs. The mean age of patient showing Her2neu 
positivity is 47yrs. (Table 29) 
TABLE 29: CORRELATION OF AGE WITH HER2 NEU POSITIVITY 
 
HER 2 
NEU 
AGE 
N MEAN 
STD. 
DEVIATION 
P-VALUE 
<40yrs >40yrs 
Positive 1(9%) 1(2.6%) 2 47.50 13.435 
0.964 Negative 10(91%) 38(97.4%) 48 47.81 9.558 
Total 11 39 50   
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In this study, 6.7% of patients with left ovarian mass, 4.3% with right 
ovarian mass showed Her2neu expression. Bilateral tumors do not show Her2neu 
positivity. (Table 30) 
TABLE 30: CORRELATION OF SITE WITH HER2NEU POSITIVITY 
VARIABLES 
HER2 NEU 
TOTAL 
P-VALUE POSITIVE NEGATIVE 
N % N % N % 
SITE 
Left 1 6.7 14 93.3 15 100.0 
0.675 Right 1 4.3 22 95.7 23 100.0 
Bilateral 0 0.0 12 100.0 12 100.0 
 
 
Among the gross morphology, Her2neu positivity was observed in 16.7% of 
cases with purely solid areas, 5.6% of cases with solid and cystic areas.(Table 31)  
TABLE 31: CORRELATION OF GROSS WITH HER2NEU POSITIVITY 
VARIABLES 
HER2 NEU 
TOTAL 
P-VALUE Positive Negative 
N % N % N % 
GROSS 
Solid 1 16.7 5 83.3 6 100.0 
0.655 
Solid/ Cystic 1 5.6 17 94.4 18 100.0 
Cystic, papillary 0 0.0 1 100.0 1 100.0 
Solid, papillary 0 0.0 15 100.0 15 100.0 
Solid/Cystic,papillary 0 0.0 6 100.0 6 100.0 
Multiloculated 0 0.0 4 100.0 4 100.0 
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In this study, the average size of the tumor measuring 12.5cm showed 
positive to Her2neu. (Table 32) 
TABLE 32: CORRELATION OF SIZE WITH HER2 NEU POSITIVITY 
VARIABLES HER2 NEU N MEAN 
STD. 
DEVIATION 
P-VALUE 
SIZE 
Negative 48 10.813 6.9248 
0.737 
Positive 2 12.500 6.3640 
 
In this study, Her 2 neu positivity was noticed in 6.1% of late stage cases 
which includes stage III & IV. (Table 33) 
TABLE 33: CORRELATION OF STAGE WITH HER2NEU POSITIVITY 
 
VARIABLES 
HER2 NEU 
TOTAL 
P-VALUE POSITIVE NEGATIVE 
N % N % N % 
Stage 
Late 2 6.1 31 93.9 33 100.0 
0.542 
Early 0 0.0 17 100.0 17 100.0 
 
Among the histological subtypes, 8.3% of endometrioid type showed 
positivity and 16.7% of mucinous carcinoma were Her2neu  positive.(Table 34) 
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TABLE 34: CORRELATION OF HISTOLOGICAL TYPE WITH 
HER2NEU POSITIVITY 
VARIABLES 
HER2 NEU 
TOTAL 
P-VALUE POSITIVE NEGATIVE 
N % N % N % 
HISTOLOGICAL 
TYPE 
Mucinous 1 16.7 5 83.3 6 100.0 
0.171 
Endometrioid 1 8.3 11 91.7 12 100.0 
Clear cell 0 0.0 3 100.0 3 100.0 
Serous papillary 0 0.0 29 100.0 29 100.0 
 
Her2neu expression is observed in 12.5% of poorly differentiated tumors. 
Grade I and II tumors does not show Her 2 neu positivity. (Table 35) 
TABLE 35: CORRELATION OF GRADE WITH HER2 NEU POSITIVITY 
VARIABLES 
HER2 NEU 
TOTAL 
P-VALUE POSITIVE NEGATIVE 
N % N % N % 
GRADE 
I 0 0.0 21 100.0 21 100.0 
0.162 II 0 0.0 13 100.0 13 100.0 
III 2 12.5 14 87.5 16 100.0 
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Her 2 neu positivity is observed in 5.3% of cases with ascites. (Table 36) 
TABLE-36:CORRELATION OF ASCITES WITH HER2 NEU POSIYIVITY 
 
VARIABLES 
HER2 NEU 
TOTAL 
P-VALUE POSITIVE NEGATIVE 
N % N % N % 
ASCITIS 
Positive 2 5.3 36 94.7 38 100.0 
0.999 Negative 0 0.0 12 100.0 12 100.0 
Total 2 4% 48 96.0 50 100.0 
 
6.7% of the cases with omentum involvement showed Her2neu 
positivity.(Table 37) 
 
TABLE 37: CORRELATION OF OMENTUM INVOLVEMENT WITH 
HER2 NEU POSITIVITY 
 
VARIABLES 
HER2 NEU 
TOTAL 
P-VALUE POSITIVE NEGATIVE 
N % N % N % 
OMENTUM 
Positive 2 6.7 28 93.3 30 100.0 
0.510 Negative 0 0.0 20 100.0 20 100.0 
                       Total 2 4.0 48 96.0 50 100.0 
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The mean CA 125 level of 137.63 IU was observed in positive cases.  (Table 38) 
TABLE 38: CORRELATION OF CA125 WITH HER2 NEU POSITIVITY 
VARIABLES HER2 NEU N MEAN 
STD. 
DEVIATION 
P-VALUE 
CA125 
Negative 48 449.26 1219.53 
0.722 
Positive 2 137.63 107.15 
 
CORRELATION OF P53 AND HER2NEU EXPRESSION WITH 
PROGNOSIS 
In this study, prognosis was analyzed for 50 patients for whom IHC was 
done. Post operatively patients were given 6 courses of cisplatin, 
cycliphosphamide regimen every 21 days and follow up of the patients were done 
for the median period of 15 months. 3 patients had pre chemotherapy and 
continued in postoperative period. Among the 50 patients with epithelial 
carcinoma, 31 patients (62%) were alive, 16 patients (32%) have died due to 
recurrence and other general cause and 3 patients (6%) had left the follow up. 
Among the patients who had survived 3 patients (9.7%) showed recurrence after 12 
months. They were given adjuvant chemotherapy .They survived well and further 
follow up was done. Prognosis of the patients with P53, Her2neu positivity and 
clinopathological parameters was analyzed with 47 patients. 3 patients who had 
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lost the follow up were not included to study the odds ratio and relative risk and 
outcome of the patients.  
P53 positivity is observed in 24 cases. Out of this 2 patients had left follow 
up. 10 patients (45.5%) were alive until the period of study. Those patients with 
recurrence showed positivity to P53 expression. 12 patients (54.5%) have died. 
This shows statistically significant association of P53 positivity (p=0.005) with 
worse survival.  
Her 2neu positivity is observed in 2 patients. 1 patient (50%) is alive and 1 
patient (50%) died. There is no significant association of Her2neu positivity 
(p=0.999) with survival of the patients. (Table 39) 
Table 39: CORRELATION OF P53 AND HER2NEU EXPRESSION WITH 
PROGNOSIS 
 
PROGNOSIS 
TOTAL  
P-VALUE 
GOOD POOR 
N % N % N % 
P53 
Positive 10 45.5 12 54.5 22 100.0 
0.005 
Negative 21 84.0 4 16.0 25 100.0 
HER2 NEU 
Positive 1 50.0 1 50.0 2 100.0 
0.999 Negative 30 66.7 15 33.3 45 100.0 
Total 31 66.0 16 34.0 47 100.0 
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STUDY OF PROGNOSTIC IMPACT OF CLINICO-PATHOLOGICAL 
AND IMMUNOHISTOCHEMICAL PARAMATERS. 
 In the present study, influence of these variables with outcome of the 
patients was evaluated. Results were reported as relative risk and 95% confidence 
interval. P value <0.005 is considered significant. 
In this study, 42.1% of the patients of age above 40 had decreased survival 
whereas all patients less than 40yrs had survived well. (Table 40 and Chart 8) 
Table 40: ASSOCIATION OF AGE GROUP WITH SURVIVAL 
 
SURVIVAL STATUS 
TOTAL 
 P-VALUE 
NON 
SURVIVAL 
SURVIVAL 
N % N % N % 
Age group (yrs) 
> 40 16 42.1 22 57.9 38 100.0 
0.017 ≤40 0 0.0 9 100.0 9 100.0 
Total 16 34.0 31 66.0 47 100.0 
 
48.4% of the patients with late stage disease had died whereas 6.3% of the 
patients with early stage had decreased survival. (Table 41 and Chart 9) 
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Table 41: ASSOCIATION OF STAGE OF DISEASE WITH SURVIVAL  
 
SURVIVAL STATUS 
TOTAL 
NON SURVIVAL SURVIVAL 
N % N % N % 
Stage 
Late 15 48.4 16 51.6 31 100.0 
Early 1 6.3 15 93.8 16 100.0 
Total 16 34.0 31 66.0 47 100.0 
 
Serous carcinoma has worst survival than other histological types. 42.9% of 
serous carcinoma patients have not survived whereas only 21.1% of the patients 
had poor survival in other types. (Table 42) 
TABLE 42:ASSOCIATION OF HISTOLOGICAL TYPE WITH SURVIVAL 
 
SURVIVAL STATUS 
TOTAL 
NON SURVIVAL SURVIVAL 
N % N % N % 
Histological 
type 
Serous 12 42.9 16 57.1 28 100.0 
Others 4 21.1 15 78.9 19 100.0 
Total 16 34.0 31 66.0 47 100.0 
 
Clear cell carcinoma has worst survival than the other histological type 
(66.7%). (Table 43)  
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TABLE 43:ASSOCIATION OF HISTOLOGICAL TYPE WITH SURVIVAL 
   
SURVIVAL STATUS 
TOTAL 
NON SURVIVAL SURVIVAL 
N % N % N % 
Histological 
type 
Clear cell 2 66.7 1 33.3 3 100.0 
Others 14 31.8 30 68.2 44 100.0 
Total 16 34.0 31 66.0 47 100.0 
 
In this study, 60% of the patients with high grade carcinoma and only 21.9% 
of the cases with low grade tumor had poor survival. (Table 44 and Chart 10) 
TABLE 44: ASSOCIATION OF GRADE WITH SURVIVAL 
 
SURVIVAL STATUS 
TOTAL 
NON SURVIVAL SURVIVAL 
N % N % N % 
Grade 
High 9 60.0 6 40.0 15 100.0 
Low 7 21.9 25 78.1 32 100.0 
Total 16 34.0 31 66.0 47 100.0 
 
44.4% of the patients presented with ascites had died. All the patients (100%) 
without ascites were alive. (Table 45 and Chart 11) 
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TABLE 45: ASSOCIATION OF ASCITES WITH SURVIVAL 
 
SURVIVAL STATUS 
TOTAL 
P-VALUE NON SURVIVAL SURVIVAL 
N % N % N % 
ASCITIS 
Positive 16 44.4 20 55.6 36 100.0 
0.009 Negative 0 0.0 11 100.0 11 100.0 
Total 16 34.0 31 66.0 47 100.0 
 
          54.5% of the P53 positive patients had worse survival, whereas only 16% of 
the patients with P53 negative had worse survival. (Table 46 and Chart 12) 
TABLE 46: ASSOCIATION OF P53 POSITIVITY WITH SURVIVAL 
 
SURVIVAL STATUS 
TOTAL 
NON SURVIVAL SURVIVAL 
N % N % N % 
P 53 
Positive 12 54.5 10 45.5 22 100.0 
Negative 4 16.0 21 84.0 25 100.0 
Total 16 34.0 31 66.0 47 100.0 
,                                                                                                        
          50% of the Her2neu positive patient had decreased survival, only 33.3% of 
the negative patients had decreased survival. (Table 47) 
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TABLE 47: ASSOCIATION OF HER2NEU POSITIVITY WITH SURVIVAL 
 
SURVIVAL STATUS 
TOTAL 
NON SURVIVAL SURVIVAL 
N % N % N % 
HER 2 NEU 
Positive 1 50.0 1 50.0 2 100.0 
Negative 15 33.3 30 66.7 45 100.0 
Total 16 34.0 31 66.0 47 100.0 
 
In this study correlation of the survival of the patients with 
clinicopathological and immunohistochemical parameters were analysed by 
calculating RR, CI and P-value. (Table 48) 
TABLE 48: RELATIVE RISK AND P-VALUE FOR SURVIVAL ANALYSIS OF 
CLINICOPATHOLOGICAL AND IHC PARAMETERS  
FACTORS RR 95%CI P- VALUE 
Age 
>40 vs<40 
- - 0.017 
Stage 
Late vs early 
7.742 1.1-53.5 0.004 
Grade 
High vs low 
2.743 1.3-5.9 0.010 
Type 
Serous vs others 
Clearcell vs others 
 
2.036 
2.095 
 
0.8-5.4 
0.8-5.2 
 
0.122 
0.216 
Ascites 
Presence vs absence 
- - 0.009 
P53 
Positive vs  negative 
3.409 1.2-9 0.005 
Her 2 neu 
Positive vs negative 
1.500 0.3-6.3 0.995 
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FIG-18. H&E.Increased layering of cells 
with stratification and nuclear atypia.(40X) 
  
ENDOMETRIOID CARCINOMA 
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FIG-20. H&E. Glands with back to 
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FIG-22.H&E.Well differentiated endometrioid 
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FIG-23.H&E.Malignat epithelial cells 
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arranged in sheets pattern. (10X) 
FIG-25.H&E.Tubulocystic pattern lined 
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FIG-26. H&E. Polyhedral cells with clear 
cytoplasm and pleomorphic nuclei. (40X). 
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DISCUSSION 
Ovarian cancer is one of the leading causes of death among all 
gynaecological malignancies. In India, Ovarian cancer is the most lethal 
gynecologic malignancy which ranks 2
nd
 after cervical cancer.  In Chennai, ovarian 
cancer stands in the third position
3
. 
Due to lack of effective screening methods, 70% of the epithelial carcinomas 
are diagnosed only at an advanced stage
74
. Various new biological markers have 
been studied as prognostic and predictive factors for the evaluation of the 
biological behavior of ovarian cancer and to improve treatment planning. Among 
these, immunohistochemical staining of P53 and Her2neu have been proposed to 
be of prognostic value. In the present study potential impact of the expression of 
P53 and Her2neu protein on the outcome of patients with malignant epithelial 
ovarian tumors and for their targeted therapy was analysed. 
Immunohistochemical evaluation was done in 50 cases of epithelial ovarian 
carcinomas and attempted to correlate the P53 and Her2neu expression with the 
known prognostic factors like age, presence of ascites, stage, grade and 
histological type of ovarian cancers. Follow up of the patients was done to assess 
the survival of the patients. 
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Madras Medical College- Institute of Obstetrics & Gynaecology, Egmore & 
Institute of Social Obstetrics and Kasthurbai Gandhi Hospital, Triplicane being a 
tertiary referral centre, total number of 850 cases with ovarian cancers was 
reported in the year 2008-2012. Among the entire ovarian specimens received for 
histopathological examination, 638 cases (75.1%) of the cases were reported to be 
surface epithelial ovarian tumors and 162(25.4%) of the cases were malignant. 
In 2008, WHO had reported 224,747 new cases of epithelial ovarian 
carcinomas in the world population. Among them, approximately 43% was 
diagnosed in women above 60 years
75
. Epithelial ovarian carcinoma was diagnosed 
after menopause in North America.  In USA approximately 50% of epithelial 
ovarian carcinoma cases were diagnosed at the age of 60 years.
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In this study, the age of epithelial ovarian cancer patients ranged from 22 to 
70 years with the mean age of 47 years. The highest incidence of epithelial ovarian 
carcinoma (42%)
 
occurred in 4th to 5 th decade and it constitutes only 6% in 6 th 
decade. This is in contrast with the study done by Murthy NS et al
14
 who observed 
incidence in the peak age of 55-64yrs and another study done by J K Chan, et al
15
 
who reported it as a disease of post menopausal age. 5.6% of serous carcinomas 
occurred in 2
nd
 to 3rd decades of life which is in contrast to the study done by 
Nandakudi SM
14
 who observed serous tumors are rare in 2
nd
 to 3 rd decade. 
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COMPARISION OF DISTRIBUTION OF TUMORS WITH SITE 
In the present study, 26.5% of the epithelial tumors showed bilateral 
involvement which is similar to the study done by Marcela F Paes, et al 
54
 who 
observed 29% of bilaterality.  
Also 31% of serous carcinomas are bilateral and 86.2% of mucinous 
carcinomas are unilateral which is in accordance to literature
22
. High frequencies of 
cases with endometrioid and clearcell carcinoma were unilateral.  
COMPARISION OF DISTRIBUTION OF TUMORS WITH SUBTYPES 
  According to literature,
64
  Serous carcinomas constitutes 30%, mucinous 
15%,endometriod  20% and clear cell 2-5% of all ovarian tumors . It showed 
concordance to study done by Marcela F Paes, et al 
54    
who showed 30% of serous 
carcinomas, 13% of mucinous and endometriod carcinoma, 2% of clear cell 
carcinoma. 
 In this study serous carcinomas constitutes highest percentage of 55.6% 
when compared to other types of epithelial tumors followed by endometriod 
carcinoma (21%) which is similar to the finding observed by Ioka A et al
77
 and 
Rangel et al
78
. Ioka A et al, reported that serous carcinoma is the most common 
histological type. Rangel et al, reported endometriod as second most common 
tumor among the epithelial ovarian carcinoma.  
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COMPARISION OF DISTRIBUTION WITH GROSS MORPHOLOGY 
In general, ovarian tumors grossly show various morphology. Serous 
carcinomas show predominant areas of solid with few cystic areas, papillary 
excrescences are more common in serous carcinomas,  mucinous carcinomas show 
multiloculated cysts.   
In this study, among the serous carcinomas 28% showed solid areas with 
papillary excrescences, 26% presented as a solid and cystic pattern, 22% cases are 
purely solid. Only 2 % cases presented as purely cystic.  48.3% of mucinous 
carcinoma presented as a multiloculated cysts compared to other types. 44 % of 
endometrioid type showed solid with cystic areas predominantly, 35.3% of cases 
were purely solid.  Clear cell carcinoma showed varying morphology like solid, 
solid cystic, solid with papillary excrescences. This is in accordance to the findings 
observed by Kurman et al. 
22
 
COMPARISION OF DISTRIBUTION WITH OVARIAN CANCER SIZE 
Among the various histological types, serous carcinomas originate from 
serous or cortical inclusion cyst. They are usually small and asymptomatic, 
because of this they present only at the advanced stage. Mucinous carcinomas are 
large multiloculated cyst, due to this they are presented with abdominal distension 
and diagnosed earlier. 
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Robert J. Kurman, M.D.et al 
27
, in their study on origin and pathogenesis of 
ovarian carcinoma showed that mucinous carcinomas are large
 
with median size of 
9cm, ranges from 5-30cm. Present study is in accordance to above finding with 
mean size of 10cm and range from 7 cm to 30 cm. Similarly, increased frequency 
of serous carcinomas presented as a smaller mass and range from 5cm to 15 cm 
which is similar to finding observed by Kurman et al. 
Due to lack of effective screening programme and since patients are 
asymptomatic, ovarian carcinomas are diagnosed at the advanced stage. In this 
study, 43.2% of patients presented at stage I , 50% of patients diagnosed at stage 
III and 6.8% at stage IV. Values of stage I & III were similar to the finding 
observed by Kim et al
79
, Ali-Fehmi R et al
80
, Badiglian Filho L et al
81
, Derchain S 
et al
82
, Marcela F Paes et al
54
.(Table 49) 
TABLE 49: COMPARISION OF OVARIAN CANCER STAGE DISTRIBUTION  
 STAGE 1 STAGE III 
Kim et al
79 
39% 42.7% 
Ali-Fehmi et al
80 
37% 43% 
Badiglial Filho et al
81 
26.3% 42% 
Derchain et al
82 
34% 51% 
Marcela F Paes et Al
54 
29% 56.2% 
Current Study 43.2% 50% 
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COMPARISION OF OVARIAN CANCER GRADE DISTRIBUTION  
In this study, grade 1 carcinomas were more common than the other grades 
of distribution. 43.2% of the tumors showed well differentiation. This is in contrast 
to the study conducted by Marcela F Paes et al
54
 who noticed the prevalence of 
grade II differentiation. Present study also showed increased number of serous 
carcinoma with grade II differentiation, mucinous carcinomas with grade I, all 
cases of clear cell carcinomas were poorly differentiated. 
COMPARISION OF DISTRIBUTION OF OVARIAN CANCER WITH 
ASCITES 
In this study, presence of ascites is seen in all cases of clear cell carcinoma 
and 85.5% of serous carcinoma and 61% of endometrioid carcinoma than the other 
types. Also 95.5% of high grade tumors presented with ascites than the low grade. 
This is in accordance to study done by Yoshimura S, et al
56
 who observed presence 
of ascites in serous carcinoma and in high grade carcinomas.  
COMPARISION OF DISTRIBUTION OVARIAN CANCER WITH CA125 
LEVEL.  
Mary T Sylvia et al 
83
, had observed that 27.56% of carcinomas showed 
normal CA125 level. Increased level is noted in advanced stage cases with the 
median of 275 IU. In this study, 10% of cases have normal CA125 level. It shows 
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exponential increase in advanced stage carcinomas ranging from 13.9 IU to 7600 
IU with median level of 129 IU which is similar to the finding observed by      
Zorn et al
84
 who reported 7.6% of malignant cases with normal CA125 level. This 
is in contrast to finding observed by Mary T Sylvia et al
83
. 
COMPARISON OF P53 AND HER2NEU EXPRESSION IN WORLD 
STATISTICS 
In this study the expression of P53 and Her 2 neu was observed in 48% and 
4% cases respectively. The proportion of  P53 expresssion  is similar to the studies 
conducted by Felip et al
60
, J C Mark et al
85
, Mary T Sylvia et al
83
,  Wood-Yee 
Chan
6
 et al. This is in contrast to several studies conducted by S.Camilleri-Broet et 
al
23
, Vassiliki et
86
 al, showing 70% of P53 expression . 
In the present study, Her 2neu expression is noted in 4% of cases. Other 
cases did not show Her2neu expression. These cases were counter checked by 
standard laboratory to rule out technical error since there is wide variation in the 
positivity. Observed results were in accordance to the study conducted by 
Marianne Tuefferd et al
87
.  
In contrast, several studies on Her2neu expression show positivity ranges 
from 6% to 38%. This fluctuation may be due to different techniques used, small 
study group and varying characteristics of the studied cases. (Table 50) 
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TABLE 50: COMPARISON OF P53 AND HER2NEU EXPRESSION IN 
WORLD STATISTICS 
 P53 
POSITIVE 
P53 
NEGATIVE 
HER2NEU 
POSITIVE 
HER2 NEU 
NEGATIVE 
Camilleri-Broet et  al
23
 71% 29% 16% 84% 
Mary T Sylvia et al
83 
57% 43% 21% 79% 
Vassiliki et al
86 
70.5% 29.5% 18% 82% 
Neilsen J S et al
88 
53% 47% 35% 65% 
J.R.Marks
85 
50% 50% NA NA 
Wood-Yee Chan et al
6 
54% 46% NA NA 
Berchuk et al
89 
NA NA 34% 66% 
Nisha narwah    et al
8
 NA NA 38% 62% 
Felip et al
60 
NA NA 22% 78% 
Haldane et al
90 
NA NA 31% 69% 
Rubin et al
91 
NA NA 24% 76% 
Marianne et al87 NA NA 6.6% 95.3% 
Current study  48% 52% 4% 96% 
 
NA- NOT APPLICABLE 
CORRELATION OF P53 EXPRESSION WITH KNOWN CLINICO- 
PATHOLOGICAL PROGNOSTIC FACTORS 
J.R Marks et al
85
 in 1991, studied on 107 patients who underwent TAH/BSO 
for ovarian cancer in Durham and demonstrated that P53 expression is associated 
with advanced stage, but there is no correlation between age, grade, and type of the 
77 
tumor. He reported that median survival was worse in patients with P53 
expression, but the difference is not statistically significant. 
 Studies done by the Gynecologic Oncology Group
92
 and others on 117 
patients of ovarian cancer have demonstrated that overexpression of P53 is 
associated with high grade tumors but not with stage, age and histological type. He 
also reported the association of P53 expression with worse survival but it was not 
statistically significant. 
Lobna Ayodi et al
93
, in 2010 studied expression of P53 with prognosis of 
ovarian cancers on Tunisian patients.  He demonstrated statistically significant 
positive correlation between P53 expression and FIGO stage (III&IV) (p=0.026) 
and presence of ascites. No correlation was noted on age, histological type and 
grade. He concluded that it is associated with worse prognosis. 
Mary t Sylvia et al
83
, in their study on 60 patients with ovarian carcinoma 
have demonstrated that P53 expression was seen in 57.6% of malignant 
carcinomas, 57.89% of serous type, 31.57% of high grade tumors, 84.2 % of the 
carcinomas showed presence of ascites. CA125 level was found to be higher 
among the serous, advanced stage, high grade tumors.   
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Shahin et al
94
 in 2000, studied on epithelial cancer patients and showed that 
there is correlation between P53 expression and advanced stage and poorly 
differentiated grade of ovarian cancer. 
Study conducted by Hartmann LC et al
95
 in 1994, have found a statistical 
significant association between P53 and tumor differentiation and no association 
with stage and histological type. 
Antilla  N A et al
96
, studied on 316 patients with ovarian carcinoma in 
Finland and observed statistical significance of P53 positivity  with tumor grade (p 
< 0.001), stage (p < 0.001) and  serous histologic type (p = 0.005). He also 
reported that P53 positivity acts as a marker of decreased overall survival in 
epithelial cancer patients.  
Klemi PJ et 
97
, studied on 136 patients of malignant epithelial cancer in 
Finland and showed that statistical significance exists between P53 expression and 
histological type ( p=0.0006), high grade( p=0.04). It does not correlate with stage, 
age at diagnosis and presence of ascites. P53 positivity is associated with poor 
survival of the patients. 
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Skirnisdottir  I et al
98
, studied on 106 patients of epithelial ovarian tumors 
and reported that there is correlation between P53 expression and tumor grade 
(p=0.007)and survival status (p=0.046) but not with stage, age and sub types.  
Neilsen J S et al
88
 , studied both uni and  multivariate analyses on 415cases 
of epithelial cancer in Denmark and reported statistical significance between P53 
positivity and the classical prognostic factors such as older age, advanced FIGO 
stage, and poorer differentiated grade. 
K.Niwa et al
99
, studied on 57 patients in Japan and showed no statistical 
significance of P53 expression on ovarian tumors with age at diagnosis, clinical 
stage or histological type. 
Study conducted by Vassiliki Malamou-Mitsi et al 
86
on p53 expression have 
demonstrated that no significant association with clincopathological parameters. 
P53 status along with older age (>63 yrs) and high grade(p=0.04) is an independent 
prognostic factor for survival on epithelial ovarian cancers.  
Multicenter study of the GINECO group 
87
on 117 patients of ovarian tumors 
had showed no association between P53 and clinicopathological paramaters. 
P53expression does not retain prognostic significance. 
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In this study, there is direct association of P53 expresssion with older age 
group. Increased frequencies of positive cases were presented at the advanced 
stage disease.  81% of the positive cases showed high grade differentiation. Ascites 
was observed in 92% of the patients with P53 positivity. Expression is seen in 66% 
of clear cell carcinoma and 55% of serous carcinoma suggesting direct association 
between P53 positivity with histological types. 
 In comparison to the above studies, there is statistically significant 
correlation between P53 positivity with advanced stage(p=0.002), high grade 
(p=0.002), and presence of ascites (p=0.013) which is similar  to the study done by 
Mary T Sylvia et al
83
, Shahin et al
94
, Neilson J S et al
88
, Anttila Ma et al
96
. There is 
no statistically significant association with age (p=0.351) and histological subtypes 
(p=0.512) which is in accordance to the study conducted by K.Niwa et al
99
, 
Vassiliki et al
86
, and Camellico et al
23
.  Also there is no statistically significant 
association of P53 expression with site (P=0.157), size (P=0.173), gross 
morphology (P=0.430) and CA125 level (P=0.714). 
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CORRELATION OF HER 2 NEU EXPRESSION WITH OTHER KNOWN 
CLINICOPATHOLOGICAL PROGNOSTIC FACTORS 
Nisha Marwah
8
 (2007), conducted a study on 75 cases of ovarian 
carcinomas. He observed that Her2 neu expression was significantly associated 
with high grade epithelial ovarian carcinomas, but the intensity of positivity does 
not correlate with tumor grade. 
Felip E et al
60
, in their study on 106 patients have shown that Her2neu 
overexpression was high in Stages III/IV disease than the Stages I/II disease         
(P = 0.057).  But there is no significant correlation between Her2neu expression 
with age, degree of differentiation and histologic subtype.  Her 2 neu expression 
patients show decreased survival when compared to those without expression. 
Neilsen JS et al
88
,  studied both uni and  multivariate analyses on 415cases 
of epithelial cancer in Denmark and reported statistical significance between 
Her2neu positivity and prognostic factors such as older age, advanced FIGO stage, 
and poorer differentiated grade 
Mary T Sylvia et al
83
, in their study on 60 patients with ovarian carcinomas 
have observed that Her2neu expression was seen in 21% of malignant 
carcinomas,71.42% of serous type, 57.14% of high grade tumor, 85.7% of the 
82 
carcinomas showed presence of ascites. CA125 level was found to be higher 
among the serous, advanced stage, high grade tumors. 
Marianne Tuefferd
87
 (2007)  studied on 320 cases of ovarian patients and 
demonstrated that there is no significant relationship between Her2 neu status and 
prognostic factors such as age, stage, histological type and grade. He reported that 
presence of ascites and high FIGO stage was retained as independent prognostic 
factor for shorter OS and PFS. Her2neu status has no impact on prognostic 
significance. 
 Rubin SC et al
91
, in their study on 105 ovarian cancer patients, reported that 
there was no statistically significant relationship between Her2 neu expression and 
clinicopathological prognostic parameters. Her2neu expression has no significance 
on survival of the patients. It does not act as an important prognostic factor on 
ovarian carcinomas. 
 Camilleri-broet et al
23
, studied on 164 ovarian cancer patients in France and 
found  that there is no significant  relationship by malignant cells and clinical 
parameters such as  histological type, grade or stage. HER-2 overexpression by 
malignant cells and presence of ascites is significantly associated with decreased 
OS and PFS.  He demonstrated that Her2neu expression is an independent 
prognostic variable on ovarian carcinomas. 
83 
  Vassiliki et al
86
 in 2007, studied on 95 ovarian patients in Greece and 
demonstrated that there is no correlation between the Her2neu expression and 
prognostic factors such as age ,stage, grade and histological types.  
 In this study, Her2neu expression is seen in only 2.6% of the patients older 
than 40 yrs (p=0.964). Only 6.1% of patients with late stage showed positivity 
(p=0.542). 8.3% of endometrioid type showed positivity and 16.7% of mucinous 
carcinoma were Her2neu positive (p=0.171). 12% of grade III tumor (p=0.162) 
showed positivity. 5.3% of cases with ascites (p=0.999) showed Her2neu 
expression. There is no direct association of Her2neu positivity with older age, site, 
size, gross morphology and histological types. There is direct association of 
Her2neu expression with advanced stage, high grade and ascites. But there is no 
statistically significant association.   
In comparision to studies done by Marianne Tuefferd
87
, Rubin SC et al
91
, 
Camilleri-broet et al
23
, vassiliki et al 
86 
, this study also shows no statistically 
significant correlation of  Her2 neu expression with the older age (p=0.964),  late   
stage(p=0.542), high grade(p=0.162)  histological types(p=0.171) and presence of 
ascites(p=0.999). This is in contrast to studies done by Mary T Sylvia et al 
83
, 
Neilsen J S et al 
88 
and Felip E et al
60
. 
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ASSOCIATION OF CLINICO-PATHOLOGICAL AND IMMUNOHISTOCHEMICAL 
PARAMETERS WITH SURVIVAL. 
Berchuck et al 
89
studied in 1990 on 50 patients of advanced epithelial cancer 
in Durham with median follow up of 15.7 months reported statistically significant 
association of Her2neu expression with poor survival.  
Survival analysis done by Camilleri-broet et al
23
, on 117 patients with 
median follow up of 68 months have estimated the statistical significance of 
Her2neu expression  with shorter OS(p=0.002, RR 2.07,95% CI 1.03-4.17)  and  
DFS(p=0.02, RR 2.13, 95% CI 1.13-4.01). Presence of ascites also considered as a 
independent prognostic factor of shorter survival.  He also reported that P53 
expression has no impact on survival. 
Survival analysis done by Marianne Tuefferd et al
87
, on 320 patients of 
advanced epithelial tumors with median follow up of 24.9 months demonstrated 
that only presence of ascites  and high FIGO stage were considered as a 
independent prognostic factor with shorter  PFS (P=0.037), (p=0.0004)respectively  
and OS(p=0.016). HER2 NEU expression has no significant impact on the 
survival.   
85 
Rubin SC et al
91
 analyzed 40 patients of ovarian cancer in New York and 
showed no statistical significant association between Her2neu expression and 
survival, stage or grade. 
Survival analysis done by Vassiliki malamou-mitsi et al
86
 on 95 patients 
with median follow up of 66 months reported that only older age(p<0.001), high 
grade(p=0.04) and P53 expression (p=0.002) are the independent prognostic 
factors for survival. 
Angiolo Gaduucci et al
100
 in their on survival analysis have shown that there 
is no correlation between P53 expression and overall and disease free survival. 
GOG study
92
 on prognostic significance of P53 mutation and overexpression 
in 81 epithelial cancer patients have shown the association of P53 expression with 
worse overall survival but no statistical significance has been achieved. P53 
mutation showed statistical significant association with shorter survival. 
In the study conducted by P De Graeff et al
4
 on Modest effect of Her2neu 
and   P53 on prognosis have suggested that they are unlikely to be a useful marker 
of prognosis in clinical practice. 
86 
Tomic S et al 
101
 and Skirnisdottir I A et al
98
 studied the P53 overexpression 
in epithelial ovarian cancer patients and showed statistical significant association 
with shorter survival. 
In this study, there is direct association of older age, late stage, high grade, 
histological type, ascites and P53 expression with poor prognosis. Decreased 
survival is observed in older age group patients. Patients diagnosed at late stage 
have shorter lifespan. They have 14 times higher risk than the early stage disease. 
Also those belonged to serous and clear cell type had shortened survival than the 
other subtypes with 2 to 4 time‟s higher risk. Those patients with high tumor grade 
had decreased survival with 2 time‟s relative risk than low grade. 44% patients 
with ascites had not survived than patients without it who had survived well. 
Similarly patients showing P53 expression had worse survival than negative 
patients. There is no direct association of Her2neu with survival of the patients. 
In the present study, there is statistically significant association of older age 
(p=0.017), advanced stage (p=0.004,RR=7.742,95% CI=1.12 to 53.5), high grade 
(p=0.010, RR= 2.74, 95% CI=1.2 to5.9), presence of ascites(p=0.009) and p53 
overexpression (p=0.005,RR=3.409,95CI=1.2 TO 9.04) with worse survival.   
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 Hence P53 status, older age, advanced stage, high grade tumors act as a 
prognostic factor showing worse survival. This is similar to study done by Tomic S 
et al
101
, and Skirnisdottir I A
98
 and Vasilliki et al
86
 but contrast to the finding 
observed by Angiolo gaduucci et al
100
, Camilleri broet et al
23
, and GOG Study. 
In this study, Her2neu expression (P=0.995, RR=1.500,95%CI=0.3 to 6.4) 
 and histological subtypes(p=0.122,RR=2.036,95%CI=0.7-5.4) have no statistically 
significant association with poor survival of the patients. Her2neu status  do not 
have impact on survival of the patients with epithelial ovarian tumors. This is in 
accordance to the study conducted by Marianne Tuefferd et al
87
, P De Graeff et al
4
, 
and Rubin SC et al
91
, but contrast to the study done by Camilleri-broet et al
23
 and 
Berchuck et al
88
. 
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SUMMARY 
 The percentage of  surface epithelial ovarian carcinoma among the 860 
ovarian carcinoma specimen  received in Department of pathology, Institute 
of  Obstetrics & Gynaecology, Egmore & Institute of Social Obstetrics  and 
Kasthurbai Gandhi Hospital, Triplicane  Madras Medical College in the year 
2008-2012 was 75.1% 
 The distribution of benign epithelial ovarian tumors were 69.1%, borderline 
tumors 5.5%, malignant carcinomas were 25.4%. 
 Epithelial ovarian carcinoma showed peak incidence in the age of 41-50 yrs.  
 Most of the cases presented as unilateral mass.  Bilaterality constitutes 27%. 
 31% of the serous tumors presented as a bilateral mass and most of the 
mucinous carcinoma (86%) were unilateral. 
 Grossly, 29.6% of the tumors showed both solid and cystic areas.  
 78.6% of the tumor with solid cystic and papillary areas was reported as 
serous tumors and 77.8% of the multiloculated cystic lesions were mucinous 
tumors. 
 The mean size of the tumor was 10cm. 66.7% of the serous carcinomas and 
83.5 of clear cell carcinoma had size of less than 10cm and 90% of the 
mucinous carcinoma had size more than 10cm. 
89 
 The most common histological type was serous carcinoma constituting about 
55.6% of cases.  
 Grade I (well differentiated) was the most common grade accounting for 
43.66%.  Based on subtype, 37.7% of the serous carcinomas were grade II, 
86% of the mucinous carcinomas were grade I. All the clear cell carcinoma 
showed grade III differentiation. 
 56.8% of the cases presented in advanced stage (III& IV) 
 Ascites was noted in 77.8% of the cases. 
 49.4% of the cases showed the omentum deposits. 
 P53 expression was observed in 48% of cases. 
 Her 2 neu expression was seen in 4% of the tumors. 
 No statistically significant association between Her 2 neu expression and 
older age, late stage disease, high grade tumor, histological types, presence 
of ascites was found. 
 P53 expression showed statistically significant association with advanced 
stage, high grade and presence of ascites. 
 There was direct association of P53 positivity with histological types like 
serous tumor, clear cell carcinoma and older age group. 
 There was no statistically significant association of P53 expression with 
older age and histological subtypes.  
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 Statistically significant association of P53 expression, older age group, 
advanced stage, high grade and presence of ascites with shortened survival 
was observed. 
 There was direct association of histological type with decreased survival, but 
it does not achieve statistical significance. 
 There was no significant association of Her 2 neu expression with poor 
survival. 
  
 
 
 
CONCLUSION 
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CONCLUSION 
In this study, the incidence of surface epithelial ovarian carcinoma was higher 
among the all ovarian cancers. Most of our patients presented in perimenopausal age 
group with peak incidence in 4 th to 5 th decades of life. The most common histological 
type was serous carcinoma. P53 expression was seen in 48% of the cases similar to 
western studies. Her2neu expression was only 4% in contrast to several other studies. 
There was a statistically significant association between P53 expression and stage, grade 
and ascites. No statistically significant correlation between Her2neu expression and 
clinicopathological parameters were observed. There was a statistically significant 
association of P53 expression, older age, advance stage, high grade tumors and presence 
of ascites with worse survival. Her2neu expression and histological types have no 
significant association with decreased survival of the patients. 
In conclusion, P53 expression influences the outcome of the epithelial ovarian 
carcinoma patients and thus, it is useful to identify the patients who are at risk of 
recurrence and worst survival.  The outcome of the patients is not influenced by Her2neu 
expression. Hence status of P53 expression along with age, stage, grade, ascites could be 
considered as a independent prognostic factor for poor survival of the patients with 
epithelial ovarian cancer. In this study, Her2neu expression does not appear to have any 
prognostic value. Hence it needs further studies to consider them as a strong prognostic 
marker.
  
 
 
 
ANNEXURE
 ANNEXURE – I 
PROFORMA 
Case number  :      Name  : 
HPE number  :      Age  : 
IP number   :                                                             Menstrual status : 
Clinical diagnosis  :       
Risk factors if any  : 
Side of ovary   : Right/Left 
Imaging    :             
CA 125 level  :            
Ascites   :                         
Specimen   : TAH/BSO, TAH/USO, Debulking surgery 
GROSS 
Specimen size  : 
Appearance   : 
Associated findings : 
 
 MICROSCOPY 
Histological subtype : 
Histological grade :         grade I/ grade II/ grade III.   
FIGO staging           : 
Associated findings : 
IHC                          : 
HER 2 NEU SCORE : 
P53 SCORE          : 
FOLLOW UP 
Chemotherapy  :     
Follow up period :      
Outcome   : 
  
 
 
 
 
  
     ANNEXURE-II   
WHO HISTOLOGICAL CLASSIFICATION OF TUMORS OF THE OVARY 
Surface epithelial–stromal tumors 
Serous tumors 
  Malignant 
    Adenocarcinoma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, 
cystadenofibroma 
Mucinous tumors 
  Malignant 
    Adenocarcinoma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, 
cystadenofibroma 
  Mucinous cystic tumor with 
pseudomxoma peritonei 
Endometrioid tumors including variants 
with squamous differentiation 
  Malignant 
    Adenocarcinoma 
    Malignant mixed müllerian tumor 
(carcinosarcoma) 
    Endometrioid stromal sarcoma (low 
grade) 
    Undifferentiated ovarian sarcoma 
  Borderline tumor 
  Benign 
    Cystadenoma, adenofibroma, 
cystadenofibroma 
Clear cell tumors 
  Malignant 
    Adenocarcinofibroma 
  Borderline tumor 
 
 Benign 
    Cystadenoma, adenofibroma, 
cystadenofibroma 
Transitional cell tumors 
  Malignant 
    Transitional cell carcinoma (non-
Brenner type) 
    Malignant Brenner tumor 
  Borderline 
  Benign 
    Brenner tumor 
Squamous cell tumors 
  Squamous cell carcinoma 
Mixed epithelial tumors (specify 
components) 
  Malignant 
  Borderline 
  Benign 
Undifferentiated and unclassified 
tumors 
  Undifferentiated carcinoma 
  Adenocarcinoma, not otherwise 
specified 
Sex-cord stromal tumors 
Granulosa-stromal cell tumors 
  Granulosa cell tumor group 
    Adult granulosa cell tumor 
    Juvenile granulosa cell tumor 
Thecoma-fibroma group 
  Thecoma, not otherwise specified 
    Typical 
    Luteinized 
  Fibroma 
  Cellular fibroma 
  Fibrosarcoma 
   
 Stromal tumor with minor sex cord 
elements 
  Sclerosing stromal tumor 
  Signet-ring stromal tumor 
  Unclassified (fibrothecoma) 
Sertoli-stromal cell tumors 
  Sertoli-Leydig cell tumor group 
    Well differentiated 
    Of intermediate differentiation 
      Variant with heterologous elements 
(specify type) 
    Poorly differentiated (sarcomatoid) 
      Variant with heterologous elements 
(specify type) 
    Retiform 
      Variant with heterologous elements 
(specify type) 
Sertoli cell tumor 
  Stromal-Leydig cell tumor 
  Sex cord-stromal tumors of mixed or 
unclassified cell types 
  Sex cord tumor with annular tubules 
  Gynandroblastoma (specify 
components) 
  Sex cord-stromal tumor, unclassified 
Steroid cell tumors 
  Stromal luteoma 
  Leydig cell tumor group 
    Hilus cell tumor 
    Leydig cell tumor, nonhilar type 
    Leydig cell tumors, not otherwise 
specified 
  Steroid cell tumor, not otherwise 
specified 
    Well differentiated 
    Malignant 
 
 
 
Germ cell tumors 
Primitive germ cell tumors 
Dysgerminoma 
Yolk sac tumor 
Embryonal carcinoma 
Polyembryoma 
Nongestational choriocarcinoma 
Mixed germ cell tumor (specify 
components) 
Biphasic or triphasic teratoma 
Immature teratoma 
Mature teratoma 
  Solid 
  Cystic 
  Fetiform teratoma (homunculus) 
Monodermal teratoma and somatic-type 
tumors associated with dermoid cysts 
Thyroid tumor group 
  Struma ovarii 
    Benign 
    Malignant (specify type) 
Cardinoid group 
Neuroectodermal tumor group 
Carcinoma group 
Melanocytic group 
  Malignant melanoma 
  Melanocytic nevus 
Sarcoma group (specify type) 
Sebaceous tumor group 
Pituitary-type tumor group 
Retinal anlage tumor group 
Others 
Germ cell sex cord-stromal tumors 
Gonadoblastoma 
  Variant with malignant germ cell 
tumor 
Mixed germ cell-sex cord-stromal tumor 
  Variant with malignant germ cell 
tumor 
 
  
 
 
 
 
 
 
Tumors of the rete ovarii 
Adenocarcinoma 
Adenoma 
Cystadenoma 
Cystadenofibroma 
Miscellaneous tumors 
Small cell carcinoma, hypercalcemic 
type 
Small cell carcinoma, pulmonary type 
Large cell neuroendocrine carcinoma 
Hepatoid carcinoma 
Primary ovarian mesothelioma 
Wilms tumor 
Gestational choriocarcinoma 
Hydatidiform mole 
Adenoid cystic carcinoma 
Basal cell tumor 
Ovarian 
Wolffian tumor 
Paraganglioma 
Myxoma 
Soft tissue tumors not specific to the 
ovary 
Others 
Tumorlike conditions 
Luteoma of pregnancy 
Stromal hyperthecosis 
Stromal hyperplasia 
Fibromatosis 
Massive ovarian edema 
Others 
Lymphoid and hematopoetic tumors 
Malignant lymphoma (specify type) 
Leukemia (specify type) 
Plasmacytoma 
Secondary tumors 
 ANNEXURE-III 
 
FIGO STAGING 
 
Stage I Growth limited to the ovaries 
 I a Growth limited to one ovary; no ascites present containing malignant 
cells. No tumor on the external surface; capsule intact 
I b  Growth limited to both ovaries; no ascites present containing  
  malignant cells. No tumor on the external surfaces; capsules intact 
I c Tumor either stage Ia or Ib, but with tumor on surface of one or  both 
ovaries or with capsule ruptured or with ascites present containing 
malignant cells or with positive peritoneal washing 
Stage II Growth involving one or both ovaries with pelvic extension 
II a  Extension and/or metastases to the uterus and/or tubes 
II b   Extension to other pelvic tissues 
II c  Tumor either stage IIa or IIb, but with tumor on surface of one or both 
ovaries; or with capsule(s) ruptured; or with ascites present containing 
malignant cells or with positive peritoneal washings. 
Stage III Tumor involving one or both ovaries with histologically confirmed 
peritoneal implants outside the pelvis and/or positive retroperitoneal or 
inguinal nodes. Superficial liver metastases equals stage III. Tumor is 
 limited to the true pelvis, but with histologically proven malignant 
extension to small bowel or omentum 
III a Tumor grossly limited to the true pelvis, with negative nodes, but with 
histologically confirmed microscopic seeding of abdominal peritoneal 
surfaces, or histologic-proven extension to small bowel or mesentery 
III b Tumor of one or both ovaries with histologically confirmed implants, 
peritoneal metastasis of abdominal peritoneal surfaces, none exceeding 
2 cm in diameter; nodes are negative 
III c Peritoneal metastasis beyond the pelvis; 2 cm in diameter and/or 
positive retroperitoneal or inguinal nodes 
Stage IV Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present, there must be positive cytology to allot a case to 
stage IV; parenchymal liver metastasis equals stage IV 
  
 ANNEXURE - IV 
IMMUNOHISTOCHEMISTRY PROCEDURE 
1. 4µ thick sections were cut from formalin fixed paraffin embedded tissue 
samples and transferred to gelatin-chrome alum coated slides. 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes x 2 
changes. 
5. The sections were washed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in appropriate 
temperature with appropriate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in running tap 
water for 5 minutes. 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (phosphate buffer) for 5 minutes x 2 
changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in phosphate buffer for 5 minutes x 2 changes.  
13. Cover the sections with power block for 15 minutes. 
 14. The sections were drained (without washing) and appropriate primary 
antibody was applied over the sections and incubated for 45 minutes. 
15. The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
16. The slides were covered with SuperEnhancer for 30 minutes. 
17. The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. Wash in phosphate buffer for 5 minutes x 2 changes. 
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1 ml 
of DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with phosphate buffer solution for 5 minutes x 2 changes. 
23. The slides are washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 seconds  
25. The slides are washed in running tap water for 3 minutes. 
26. The slides are air dried, cleared with xylene and mounted with DPX. 
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MASTER CHART 
 
S.No HPE AGE PROCEDURE SITE GROSS SIZE CA125 STAGE 
HISTOLOGICAL 
TYPE GRADE ASCITIS  OMENTUM 
HER 2 
NEU P53 
CHEMO 
CYCLES 
FOLLOW 
UP MONTH OUTCOME 
1 101 / 08 50 TAH/BSO L  S/C 17X11X6 
 
IC MIXEDTUMORS III PR N - - - - - 
2 568 / 08 55 TAH/BSO R  S 6X5X4 
 
IV SER CA III A N - - - - - 
3 893 / 08 40 TAH/BSO R C 5X1X1 
 
IV SER CA III A N - - - - - 
4 970 / 08 37 TAH/BSO L C 7X6X4 
 
IC MUC CA I PR N - - - - - 
5 1193 / 08 50 TAH/BSO L S,PAP 10X8X6 
 
IC SER CA I PR N - - - - - 
6 1280 / 08 40 TAH/BSO R S 20X8X6 
 
IIIC SER CA I PR P  - - - - - 
7 1710 / 08 42 DBS L MLC 28X12X11 
 
IVB MUC CA I PR N - - - - - 
8 1911/08 55 TAH/BSO B  S/C 12X9X3,6X3X2 
 
IC END CA II PR N - - - - - 
9 1926 / 08 52 TAH/BSO B C,PAP 14X11X2,3X2X2 
 
IC END CA I PR N - - - - - 
10 2028 / 08 48 TAH/BSO L S 6X3X2 
 
IC SER CA II PR N - - - - - 
11 2119 / 08 60 TAH/BSO L C,PAP 5X3X2 
 
IIIC SER CA II PR P  - - - - - 
12 2151/08 47 TAH/BSO L S,PAP 5X3X2 
 
IC SER CA III PR N - - - - - 
13 2203 / 08 40 TAH/BSO L S,PAP 13X10X8 
 
IC SER CA II PR N - - - - - 
14 2555/08 53 TAH/BSO L MLC 18X15X10 
 
IIIC MUC CA II PR P  - - - - - 
15 2443 / 08 55 DBS R S 5X3X2 
 
IVB SER CA II PR N - - - - - 
16 2609 / 08  38 TAH/BSO L S,PAP 5x4x3 
 
IC SER CA I PR N - - - - - 
17 2625 / 08 35 TAH/BSO B MLC 30X30X20 
 
IIIC MUC CA I PR P  - - - - - 
18 2692 / 08 41 TAH/BSO B S,PAP 15X14X8,6X6X4 
 
IIIC SER CA II PR P  - - - - - 
19 2781 / 08 39 TAH/BSO L MLC 15X10X8 
 
IC MUC CA I PR N - - - - - 
20 2782 /08  55 TAH/BSO R S/C 25X12X10 
 
IIIC SER CA II PR N - - - - - 
21 3047 / 08 65 TAH/BSO R C 6X6X4 
 
IIIC MIXED TUMOR II PR N - - - - - 
22 3106 / 08 36 TAH/BSO L S/C 14X10X6 
 
IIIC SER CA II PR P  - - - - - 
23 3153/08 60 DBS R S 5X3X2 
 
IV SER CA III PR P  - - - - - 
24 3171/08 46 TAH/BSO B S,PAP 17X13X6,10X8X6 
 
IIIC SER CA III PR P  - - - - - 
25 3248 / 08 51 TAH/BSO R S/C 9X8X5 
 
IIIC SER CA III PR N - - - - - 
26 3273 / 08 45 TAH/BSO B S/C 18X5X6 
 
IC END CA I PR N - - - - - 
27 3282/08 47 TAH/BSO R MLC 17X14X3 
 
IIIC SER CA I PR P  - - - - - 
28 3298 /08 63 TAH/BSO B S/C 15X9X5 
 
IC MUC CA I A N - - - - - 
29 3310 / 08 43 TAH/BSO B S/C,PAP 19X17X8 
 
IC/IIIA SER CA III PR P  - - - - - 
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30 3327 / 08 48 TAH/BSO R S 10X8X3 
 
IC SER CA I PR N - - - - - 
31 3370 / 08  60 TAH/BSO L MLC 5X4X3  
 
IC MUC CA I PR N - - - - - 
32 3440 / 08 47 TAH/BSO B S/C 12X8X7 
 
IIIC SER CA II PR P  - - - - - 
33 3494/08 42 TAH/BSO R S,PAP 7X5X5 
 
IIIC SER CA II PR P  - - - - - 
34 3554/08 45 TAH/RSO R S/C 16X16X8 
 
IC END CA II PR N - - - - - 
35 3608 / 08 45 DBS B S,PAP 10X10X7 
 
IV SER CA II PR P  - - - - - 
36 3622 / 08 50 DBS B S 5X3X2 
 
IV SER CA II PR N - - - - - 
37 3809 / 08 60 TAH/BSO L C,PAP 16X10X5 
 
IIIC SER CA II PR P  - - - - - 
38 136 / 09 43 TAH/BSO L MLC 15X20X12 
 
IIIA MUC CA I A P  - - - - - 
39 168/09 37 TAH/BSO L S 12X10X7 
 
IIIC SER CA III PR P  - - - - - 
40 226/09 53 TAH/BSO B S/C,PAP 8X4X3 
 
IIIC SER CA I PR P  - - - - - 
41 367 / 09 30 TAH/BSO B S 10X7X6 
 
IIIC MIXED TUMORS III PR P  - - - - - 
42 424 / 09  58 TAH/BSO R S 16X14X5 
 
IIIB SER CA III PR P  - - - - - 
43 629/ 09 45 TAH/BSO B S/C  5X4X2,5X2X2 
 
IC END CA II PR N - - - - - 
44 654 / 09 40 DBS R S 5X3X3 
 
IV END CA II A N - - - - - 
45 658/09 62 TAH/BSO L C,PAP 15X9X5 
 
IA END CA I A N - - - - - 
46 799/09 40 TAH/BSO R S,PAP 20X20X10 
 
IC MUC CA II PR N - - - - - 
47 1200 / 09 43 TAH/BSO R S 10X10X8 
 
IA END CA II A N - - - - - 
48 1202 / 09 48 TAH/BSO L S,PAP 10X10X8 
 
IIIC END CA II PR P  - - - - - 
49 1203 / 09 35 TAH/BSO B S/C,PAP 6x5x4,5x3x2 
 
IIIC SER CA I PR P  - - - - - 
50 1294 / 09 56 TAH/BSO B S/C 18X17X9,14X10X7  IIIC END CA II PR P  - - - - - 
51 1479 / 09 42 TAH/BSO R c  12x11x10 
 
IC SER CA I PR N - - - - - 
52 1508 / 09 45 TAH/BSO R S/C,PAP 12X10X8 
 
IIIC SER CA III PR P  - - - - - 
53 1937 / 09 41 TAH/BSO B S/C 10x8x7,9x3 169.7 IIIC SER CA III PR P  N N 6 22 NS 
54 1967 / 09 49 TAH/BSO B S/C 7X4X2, 5X3X2 345.7 III SER CA II PR P  N N 6 16 NS 
55 2188 / 09 42 TAH/BSO L S,PAP 10X5X5 
 
IIIC SER CA III PR P  - - - - - 
56 2410 / 09 57 TAH/BSO R S 8X4X3 61.86 IIIC END CA III PR P  P P 1 2 NS 
57 2413 / 09 40 TAH/BSO B S/C 12X10X7 
 
IIIC END CA I PR P  - - - - - 
58 2420 / 09 70 TAHLSO L C,PAP 10X10X3 13.9 IIIC END CA III PR P  N P 1 - LFU 
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59 2738 / 09 45 TAH/BSO B S,PAP 5X3X2 333.9 IIIC 
CLEAR CELL 
CARCINOMA III PR P  N P 3 8 NS 
60 3097 / 09 50 TAH/BSO R S,PAP 5X4X2 231.6 IIIC SER CA II PR P  N P 6 15 NS 
61 3256 / 09 47 TAH/BSO R C 5X5X3 
 
IA MUC CA I A N - - - - - 
62 3291 / 09 50 TAH/BSO L MLC 30X20X11 
 
IIIC MUC CA III PR P  - - - - - 
63 3463 / 09 45 TAH/BSO L MLC 15X10X9 
 
IIIC MUC CA I PR P  - - - - - 
64 3501 / 09 41 DBS R S 5X4X3 
 
IV SER CA III PR P  - - - - - 
65 3873 / 09 57 TAH/BSO B S,PAP 6X5X3 142.8 IIIC SER CA II PR P  N P 5 19 NS 
66 3978 / 09 57 TAH/BSO B MLC 8X5X3.5 
 
IIIC SER CA II PR P  - - - - - 
67 4008 / 09 46 TAH/BSO B S/C 12X10X8 
 
IIIC SER CA I PR P  - - - - - 
68 4103 / 09 57 TAH/BSO L S 5X2X1 
 
IIIA 
CLEAR CELL 
CARCINOMA III PR P  - - - - - 
69 134 / 10 44 TAH/BSO R S 6X5X3 189 IIIC SER CA III PR N N P 6 12 NS 
70 189 / 10 50 TAH/BSO L S/C 14X10X5 99.5 IIIC SER CA III PR P  N P 6 18 NS 
71 473 / 10 26 TAH/BSO B S/C,PAP 5.5X4X3, 1.5X1X1 52.3 IC SER CA I PR N N N 6 31 S 
72 475 / 10 50 TAH/BSO R S/C 14X10X8 
 
IC END CA I PR N - - - - - 
73 752 / 10 42 TAH/BSO R S 5X2X1 
 
IIIC SER CA I PR N - - - - - 
74 784 / 10 47 TAH/BSO R MLC 28X12X11 112 IC SER CA I PR N N N 6 30 S 
75 1110 / 10 45 TAH/BSO B C,PAP 5X4X3, 3X3X2 
 
IA SER CA II A N - - - - - 
76 1165 / 10 25 TAH/BSO R C,PAP 11X11X7 
 
IA MUC CA I A N - - - - - 
77 1184 / 10 65 TAH/BSO R S,PAP 7X4X5 95.4 IIIC SER CA III PR P  N P 6 15 NS 
78 1197 / 10 44 TAH/BSO L S/C 11X11X7 126.9 IIIC 
CLEAR CELL 
CARCINOMA III PR P  N P 3 6 NS 
79 1609 / 10 59 TAH/BSO R S/C 35X20X15 23.9 IA MUC CA I A N N N 6 26 S 
80 1638 / 10 53 TAH/BSO L S/C 10X8X5 84.6 IC END CA I PR N N N 6 26 S 
81 1754 / 10 46 TAH/BSO B S,PAP 5X3X2, 3X2X1 99.5 IIIC SER CA I PR P  N P 6 15 NS 
82 1906 / 10 43 TAH/BSO R S 7X5X3 112 IC END CA I PR N N N 6 25 S 
83 2322 / 10 50 TAH/BSO R C 20X6X6 
 
IA MUC CA I A N - - - - - 
84 2332 /10 39 TAH/BSO L S 6X4X3 
 
IC 
CLEAR CELL 
CARCINOMA III PR N - - - - - 
85 2337 / 10 45 TAH/BSO L S 5X2X1 
 
IA SER CA I A N - - - - - 
86 2582/10 45 TAH/BSO R C,PAP 12x11x4 
 
IIIC SER CA I PR P  - - - - - 
87 2756 / 10 43 TAH/BSO R S/C 17X11X6 32.3 IIIC MUC CA I PR P  N N 6 24 S 
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88 2884 / 10 47 TAH/BSO B S 5X2X1, 3X2X1 
 
IA END CA I A N - - - - - 
89 3052 / 10 54 TAH/BSO B S,PAP 8X6X4, 5X4X3 156.9 IIIC SER CA II PR P  N N 6 23 S 
90 3142 / 10 52 TAH/BSO R MLC 18X7X9 45.5 IA MUC CA I A N - - - - - 
91 3221 / 10 56 TAH/BSO R C,PAP 9X7.5X1 
 
III SER CA I A P  - - - - - 
92 3274/10 50 TAH/BSO R S 15X7X5 
 
IA END CA I A N - - - - - 
93 3350/10 55 TAH/BSO R S 5X2X1 185.5 IIIC SER CA III PR P  - - - - - 
94 3408/10 59 TAH/BSO B C 10X6X4, 5X2X1 
 
IC MUC CA I PR N - - - - - 
95 285 / 11 55 TAH/BSO R S 5X1.5X1 98.5 IIIC SER CA I PR N N N 6 21 S 
96 566 / 11 55 TAH/BSO L S,PAP 8.5X5X4 342.6 IIIC SER CA III PR P  N P 6 20 S 
97 1184 / 11 55 TAH/BSO R MLC 16X11X4 
 
IC MUC CA I PR N - - - - - 
98 1447 / 11 48 TAH/BSO R S 13X9X7 112.4 IIIC END CA II PR P  N P 6 19 S 
99 1503 / 11 54 TAH/BSO R S/C 6X5X3 198.8 IIIC SER CA II PR P  N N 6 11 NS 
100 1658 / 11 49 TAH/BSO R S/C 5X2X1 28.25 IA SER CA II A N N P 6 18 S 
101 1684 / 11 50 TAH/BSO R S 5X2X1 25.4 IC SER CA I PR N N N 6 18 S 
102 2010 / 11 53 TAH/BSO R MLC 21X17X5 243.7 IC/IIIA MUC CA I PR P  N N 6 12 NS 
103 2422/11 47 TAH/BSO L S,PAP 12X11X2 65.3 IIIA SER CA I PR P  N N 6 16 S 
104 2499/11 48 TAH/BSO B S/C 10X7X7,11X10X2 54.3 IIIC END CA I A P  N N 6 16 S 
105 2755/11 45 TAH/BSO R S 11X8X7 
 
IA END CA I A N - - - - - 
106 2844/11 38 TAH/BSO R S/C,PAP 20X13X7 72.1 III MUC CA I PR N N P 2 - LFU 
107 3304/11 60 TAH/BSO L S/C 9X5X4 
 
IV END CA III PR P  - - - - - 
108 3436/11 40 TAH/BSO R S,PAP 5X3X2 216.2 III END CA II A N N N 6 15 S 
109 103/12 58 TAH/BSO L S,PAP 8X5X3.5 3224.4 IIIC SER CA III PR P  N P 6 7 NS 
110 217/12 27 TAH/BSO R S/C,PAP 23X20X12 131.2 IC/IIIA SER CA I A N N N 1 - LFU 
111 251/12 28 TAH/BSO B S,PAP 6X3X2 174.2 IA SER CA I A N N P 6 9 S 
112 326/12 35 TAH/BSO L S/C 11X4X3 207.7 IC END CA I PR N N P 6 8 S 
113 607/12 28 TAH/BSO L MLC 20X20X12 45.2 IA MUC CA I A N N N 6 7 S 
114 1015/12 65 TAH/BSO R MLC 25X15X10 
 
IA MUC CA I A N - - - - - 
115 1031/12 50 TAH/BSO B S,PAP 8X3X2 148.2 IIIC SER CA III PR P  N P 3 3 NS 
116 1055/12 42 TAH/BSO L S/C 10X8X5 19.4 IC SER CA II PR N - - - - - 
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117 1110/12 40 TAH/BSO B S,PAP 5X2X1 98.9 IIIC SER CA III PR P  N N 6 6 S 
118 1262/12 39 TAH/BSO L S,PAP 8X5X4 2473 IIIC SER CA III PR P  N P 6 5 S 
119 1440/12 46 TAH/LSO L S,PAP 6X4X3 342.1 IC 
CLEAR CELL 
CARCINOMA III PR N N N 4 4 S 
120 1514/12 51 TAH/RSO R S/C 11X6X4 2014 IC END CA I A N N N 4 4 S 
121 1587/12 52 TAH/BSO R S/C 8X4X3 45.6 IA SER CA I A N N N 4 4 S 
122 1666/12 39 TAH/BSO L S/C 9X5X4 
 
IA END CA I A N - - - - - 
123 2104/12 40 TAH/BSO L S/C 7X5X4 
 
IIIC 
CLEAR CELL 
CARCINOMA III PR P  - - - - - 
124 2183/12 61 TAH/BSO R S 5X4X2 
 
IC SER CA III PR N - - - - - 
125 2220/12 54 TAH/BSO R S 9X4X2 
 
IC END CA III PR N - - - - - 
126 2370/12 35 TAH/BSO R S 7X4X3 
 
IV SER CA III PR P  - - - - - 
127 35/08 55 TAH/BSO L S,PAP 6x4x3 
 
IIIC SER CA I PR P  - - - - - 
128 1108/08 45 TAH/BSO R S 7X5X2 
 
IA END CA I A N - - - - - 
129 1642/08 62 TAH/BSO B MLC 15X13X10 
 
IC MUC CA I PR N - - - - - 
130 2001/08 50 TAH/BSO R S/C,PAP 12X10X6 
 
IIIC SER CA III PR P  - - - - - 
131 2427/08 49 TAH/BSO B S/C 11X8X4 
 
IA SER CA II  A N - - - - - 
132 2426/08 28 TAH/BSO R S  9X5X4 
 
IC SER CA I  PR N - - - - - 
133 2467/08 58 TAH/BSO R S/C 11X8X4 
 
IC SER CA I  PR N - - - - - 
134 2549/08 42 TAH/BSO L S/C,PAP 15X11X8 
 
IIIC SER CA II  PR P  - - - - - 
135 2731/08 45 TAH/BSO B S,PAP 11X6X3,8X5X3 
 
IIIC SER CA I  PR P  - - - - - 
136 731/09 35 TAH/BSO R S 9X5X4 
 
IC END CA I PR N - - - - - 
137 777/09 22 TAH/BSO B S/C,PAP 5X4X3 
 
I SER CA I A N - - - - - 
138 785/09 56 TAH/BSO R S/C 9X5X4 177.7 IIIC SER CA II PR P  - - - - - 
139 960/09 45 TAH/BSO L S/C 12X10X8 
 
IC MUC CA I PR N - - - - - 
140 2203/09 55 TAH/BSO R S,PAP 8X5X4  
 
IIIC SER CA II PR P  - - - - - 
141 2552/09 46 TAH/BSO R S/C 11X8X5 45.59 IIIC SER CA III PR P  - - - - - 
142 2569/09 55 TAH/BSO B S 12X8X6 
 
IC END CA III PR N - - - - - 
143 2788/09 55 TAH/BSO L S,PAP 9X5X4 192.2 IIIC SER CA II PR P  - - - - - 
144 PW77/09 40 TAH/BSO L C,PAP 12X10X6 
 
III  MUC CA I A P  - - - - - 
145 63/10 45 TAH/BSO B S/C 8X5X3 
 
IA SER CA II A N - - - - - 
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146 69/10 60 TAH/BSO B S/C,PAP 12X1OX6 45 IIIC SER CA II PR P  - - - - - 
147 1442/10 64 TAH/BSO R S 9X5X4 
 
IC SER CA III PR N - - - - - 
148 1721/10 35 TAH/BSO B S/C 5X4X3 
 
IIIC SER CA II PR P  - - - - - 
149 1835/10 36 TAH/BSO L S/C,PAP 7X8X3 312.3 III END CA I A P  N N 6 24 S 
150 1747/10 45 TAH/BSO R S/C 9X5X3 
 
IC END CA III PR N - - - - - 
151 2540/10 47 ST/LSO L MLC 8X5X3 203.8 IIIC SER CA II PR P  N P 6 20 S 
152 428/11 42 TAH/BSO R S/C 14X8X6 
 
IC MUC CA I PR N - - - - - 
153 652/11 60 TAH/BSO B S/C 12X11X9 
 
IC SER CA II PR N - - - - - 
154 976/11 60 TAH/BSO R S/C 11X9X7 
 
IIIC MUC CA I PR P  - - - - - 
155 1462/11 62 TAH/BSO L S/C,PAP 10X8X6 136.7 IIIC SER CA III PR P  N P 4 18 NS 
156 1641/11 40 TAH/BSO R S/C 10X6X4 
 
IIIC SER CA II PR P  - - - - - 
157 181/12 49 TAH/BSO B S/C 6X3X3,12X7X3 78.9 IIIC SER CA I PR P  N P 6 9 S 
158 523/12 55 TAH/RSO R S/C 20X12X6 102 IIIC SER CA II PR P  N P 6 8 S 
159 828/12 55 TAH/BSO R S/C 9X5X3 234.5 IA SER CA II A N N N 6 6 S 
160 1105/12 58 TAH/BSO R S/C,PAP 22X13X7 7600 IIIC END CA II PR P  N N 5 5 S 
161 1190/12 56 TAH/BSO R S/C 18X10X6 112.4 IA END CA II A N N N 4 4 S 
162 902/12 38 TAH/BSO L S/C 17X10X7 213.4 IIIC MUC CA III PR P  P P 6 6 S 
 KEY TO MASTER CHART 
 
TAH/BSO  : Transabdominal hysterectomy and bilateral saphingo oophorectomy. 
TAH/RSO  : Transabdominal hysterectomy and right salphingooophorectomy 
TAH/LSO  : Transabdominal hysterectomy and left salphingooophorectomy 
DBS  : Debulking surgery 
R  : Right ovarian mass 
L  : Left ovarian mass 
B  : Bilateral ovarian mass 
S  : Solid 
C  : Cystic 
S/C  : Solid cystic 
S/C PAP : Solid cystic papillary excrescences 
MLC  : Multiloculated cyst 
SER CA : Serous carcinoma 
MUC CA : Mucinous carcinoma 
END CA : Endometrioid carcinoma 
PR  : Present 
A  : Absent 
P  : Positive 
N  : Negative 
S  : Survival 
NS  : Non survival 
LFU  : Lost follow up 
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  ABSTRACT  
 
INTRODUCTION 
  
Among the various gynecological tumors, the pathology of ovarian 
neoplasms is more complex, because the ovary gives rise to various types of 
tumors than any other organ. They are usually dangerous because of their silent 
growth. The role of p53 and Her2neu expression in ovarian carcinoma is far from 
being fully established.  
AIM OF THE STUDY 
To evaluate the incidence and distribution of  surface epithelial ovarian 
carcinoma in patients admitted in  Institute of Obstetrics & Gynaecology, Egmore 
&  Institute of Social Obstetrics  and Kasthurbai Gandhi Hospital, Triplicane 
,Madras Medical College, Chennai during the year 2008-2012 and to evaluate the 
expression of p53 and Her2 neu in epithelial ovarian carcinoma and correlate the 
findings with several clinico-pathological features and prognosis.  
MATERIALS AND METHODS  
 
Formalin-fixed paraffin-embedded tissue samples from 50 patients of 
ovarian carcinoma  were studied by immunohistochemistry, using monoclonal 
antibodies to p53 and Her 2neu. The results were correlated with clinico-
pathological features. 
.  
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RESULTS  
P53 expression was observed in 48% of cases. Her 2 neu expression was 
seen in 4% of the tumors. No statistically significant association between Her 2 
neu expression and older age, late stage disease, high grade tumor, histological 
types, presence of ascites was found. P53 expression showed statistically 
significant association with advanced stage, high grade and presence of ascites but  
no statistically significant association of  with older age and histological subtypes. 
Statistically significant association of P53 expression, older age group, advanced 
stage, high grade and presence of ascites with shortened survival was observed. 
There was no significant association of Her 2 neu expression with poor survival. 
CONCLUSION  
In conclusion, P53 expression influences the outcome of the epithelial 
ovarian carcinoma patients and thus, it is useful to identify the patients who are at 
risk of recurrence and worst survival. The outcome of the patients is not influenced 
by Her2neu expression. Hence status of P53 expression along with age, stage, 
grade, ascites could be considered as a independent prognostic factor for poor 
survival of the patients with epithelial ovarian cancer. In this study, Her2neu 
expression does not appear to have any prognostic value.  
KEYWORDS: Surface epithelial ovarian carcinoma, P 53, Her 2 neu 
